  
    
 
  
 
CARBO CLEAR  PEDICLE  
SCREW SYSTEM  
 
CLINICAL STUDY PROTOCOL  
 
 
 
May 2017  
 
 
CONFIDENTIAL  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 2 of 117  
 
TABLE OF CONTENTS  
1. GENERAL  ................................ ................................ ................................ ................................ ........  4 
1.1. STUDY SPONSOR  ................................ ................................ ................................ ...........................  4 
1.2. INVESTIGATIONAL DEVICE MANUFACTURER  ................................ ................................ ...... 4 
1.3. INVESTIGATOR AND INVESTIGATION SITE  ................................ ................................ ...........  4 
1.4. STUDY  MONITOR  ................................ ................................ ................................ ..........................  5 
1.5. PROTOCOL  SIGNATURES  ................................ ................................ ................................ ............  5 
2. CLINICAL STUDY SYNOPSIS  ................................ ................................ ................................ ...... 6 
3. INTRODUCTION  ................................ ................................ ................................ ...........................  12 
4. DEVICE DESCRIPTION  ................................ ................................ ................................ ................  16 
4.1 DEVICE  INTENDED  USE/INDICATIONS  FOR  USE  ................................ ................................ .. 16 
4.2 SYSTEM  DESCRIPTION  ................................ ................................ ................................ ...............  16 
4.2.1  IMPLANT DESCRIPTION  ................................ ................................ ................................ ............  16 
4.2.2  SURGICAL INSTRUMENTS  ................................ ................................ ................................ ........  22 
4.2.3  PRINCIPLES OF OPERATION  ................................ ................................ ................................ ..... 27 
5. INVESTIGATIONAL PLAN  ................................ ................................ ................................ ..........  28 
5.1 PURPOSE  ................................ ................................ ................................ ................................ ....... 28 
5.1.1  OUTCOME MEASURES  ................................ ................................ ................................ ...............  28 
5.2 STUDY  DESIGN  ................................ ................................ ................................ ............................  28 
5.2.1  LITERATURE CONTROL  ................................ ................................ ................................ .............  31 
5.3 INCLUSION  CRITERIA  ................................ ................................ ................................ ................  48 
5.4 EXCLUSION  CRITERIA  ................................ ................................ ................................ ...............  49 
5.5 NUMBER  OF PATIENTS  AND  PATIENT  SELECTION  ................................ .............................  51 
5.6 STUDY  SITES  ................................ ................................ ................................ ................................  52 
5.7 STUDY  DURATION  ................................ ................................ ................................ ......................  52 
5.8 MISSING  DATA  ................................ ................................ ................................ .............................  53 
5.9 PROCEDURES  ................................ ................................ ................................ ...............................  54 
5.9.1  PREOPERATIVE MANAGEM ENT  ................................ ................................ ..............................  54 
5.9.2  SURGICAL PROCEDURE  ................................ ................................ ................................ ............  55 
5.9.3  POSTOPERATIVE MANAGE MENT ................................ ................................ ............................  55 
5.10 EVALUATION  OF PRIMARY  OUTCOME  MEASURES  ................................ ............................  59 
5.10.1  FUSION EVALUATION  ................................ ................................ ................................ ................  59 
5.10.2  PAIN AND FUNCTION EV ALUATION  ................................ ................................ ......................  62 
5.10.3  SAFETY EVALUATION  ................................ ................................ ................................ ...............  63 
5.11 EVALUATION  OF SECONDARY  OUTCOME  MEASURES  ................................ ......................  66 
5.12 STUDY  SUCCESS  CRITERIA  ................................ ................................ ................................ ....... 67 
5.13 STATISTICAL  ANALYSIS  ................................ ................................ ................................ ...........  70 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 3 of 117  
 
5.13.1  SAMPLE SIZE JUSTIFIC ATION  ................................ ................................ ................................ .. 70 
5.13.2  POOLABILITY OF DATA  ................................ ................................ ................................ .............  71 
5.13.3  ANALYSIS POPULATIONS  ................................ ................................ ................................ .........  73 
5.13.4  STATISTICAL ANALYSIS  OF DATA  ................................ ................................ .........................  73 
5.14 SUMMARY  OF RISK  ANALYSIS  ................................ ................................ ................................  75 
5.14.1  POSSIBLE HAZARDS  ................................ ................................ ................................ ...................  75 
5.14.2  RISK REDUCTION MEASU RES ................................ ................................ ................................ .. 78 
5.14.3  POTENTIAL BENEFITS  ................................ ................................ ................................ ................  90 
5.14.4  ADVERSE EVENTS  ................................ ................................ ................................ ......................  90 
5.15 INFORMED  CONSENT  ................................ ................................ ................................ ...............  106 
5.16 CASE  REPORT  FORMS ................................ ................................ ................................ ...............  107 
5.17 CONFIDENTIALITY  ................................ ................................ ................................ ...................  107 
5.18 MONITORING  ................................ ................................ ................................ .............................  108 
5.19 OPERATI ONAL  ISSUES  ................................ ................................ ................................ .............  113 
5.19.1  TRAINING  ................................ ................................ ................................ ................................ .... 113 
5.19.2  SUPPLY AND STORAGE ( ACCOUNTABILITY)  ................................ ................................ ..... 113 
5.19.3  TRACEABILITY OF DEVI CES AND DOCUMENTS  ................................ ...............................  114 
5.19.4  RECORD RETENTION  ................................ ................................ ................................ ................  114 
5.19.5  AMENDMENTS  ................................ ................................ ................................ ...........................  115 
5.19.6  DEVIATIONS FROM PROT OCOL  ................................ ................................ .............................  115 
5.19.7  PUBLICATION  ................................ ................................ ................................ ............................  116 
 
 APPENDICES………………………… ……………………………………… ….…… …....…..117 
 
 
Confidentiality Statement  
This Investigat ional Protocol  contains confidential information for the sole information 
and use of the principal investigator and its designated representatives participating in 
this clinical investigation, and the IRB /EC. It should be held confidential and 
maintained in a secure loc ation. It should not be copied or made available for review by 
any unauthorized person or firm . 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 4 of 117  
 
1. GENERAL  
1.1. STUDY SPONSOR  
The proposed study for the Carbo Clear  Pedicle Screw System will be sponsored by:  
 
Sponsor  Name : CarboFix Orthopedics , Inc. 
Address:  7183 Beach Drive SW, Ste 1, Ocean Isle Beach, NC 28469, USA  
Tel: 1-800-4080120; 910-208-9406  
Fax: 877-705-3567  
E-Mail:   hila@carbo -fix.com  
 
1.2. INVESTIGATIONAL DEVI CE MANUFACTURER  
Sponsor Name : CarboFix Orthopedics  Ltd. 
Address:  11 Ha'Hoshlim Street , Herzeliya 4672411, Israel  
Tel: Tel: +972 -9-9511511  
Fax: Fax: +972 -9-9548939  
E-Mail:  hila@carbo -fix.com  
 
1.3. INVESTIGATOR AND INV ESTIGATION SITE  
Investigator Name:   
Investigator Position:   
Investigation Site:   
Address:   
Tel:  
Fax:  
E-Mail:   
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 5 of 117  
 
1.4. STUDY  MONITOR  
Monitoring of the study at US sites wi ll be performed by the following  Clinical Research 
Associate  (CRA):  
CRA Name : Colleen Smith CCS Research, Inc.   
 CCS Research, Inc. , Massachusetts , USA  
E-Mail:  Colleen@carbo -fix.com   
 
 
1.5. PROTOCOL  SIGNATURES  
Sponsor Representative:  
 
 
Name   Title   Signature   Date  
 
 
Investigator:  
I have read this Protocol and agree to adhere to the requirements. I will provide copies of 
this Protocol and all pertinent information to all site personnel involved in this study. I will 
discuss this  material with them and ensure they are fully informed regarding the 
investigational product and  the con duct of the study.  
 
 
 
Name   Title   Signature   Date  
 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 6 of 117  
 
2. CLINICAL STUDY SYNOP SIS    
Device Name:  
 Carbo Clear  Pedicle Screw System  ("CarboClear System") .  
  
Regulatory Status:  Investigational Device ; Exclusively for use in clinical 
investigations.  
 
Study Design:  A prospective, multi -center, confirmatory, single arm, study . 
Results of the study will be compared to data from the literature . 
 
Purpose:  To demonstrate the safety and effectiveness of the CarboClear 
System, for skeletally mature DDD patients undergoing one level 
spinal fusion  in combination  with interbody fusion device, and 
requiring immediate, rigid, posterior spinal stabilization of the 
lumbar and /or sacral spine .  
 
Intended Use:  The CarboClear Pedicle Screw System is intended to provide rigid 
immobilization and stabilization of lumbar and/or sacral segments 
as an adjunct to fusion in patients with degenerative disc disease 
(DDD) at one level from L2 to S1, with up to Grade I 
spondylolisthesis. DDD is defined as back pain of discogenic ori gin 
with degeneration of the disc confirmed by history and radiographic 
studies. Patients should be skeletally mature and have at least six 
months of non -operative treatment.  
The CarboClear Pedicle Screw System is designed for use with 
intervertebral body fusion device and with autogenous and/or 
allogenic bone graft comprised of cancellous and/or 
corticocancellous bone graft.  
 
Procedure:  Implantation of the investigational device and an FDA cleared 
PEEK interbody fusion device (either Medtronic's  Capstone PEEK 
Spinal System, or Medtronic's  Crescent  PEEK Spinal System), 
using PLIF or TLIF. Posterolateral spinal fusion may also be 
performed, according to the physician discretion, using autogenic 
bone graft (from local and/or iliac crest bo ne) and/or  allogenic bone 
graft.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 7 of 117  
 
Number of Subjects : A total of 55 subjects will participate in the study, with u p to 1 5 
patients recruited in this site.  At least 30 patients will be enrolled in 
US sites.  
 
 Study Duration : The study is expected to last up to 36 months (total duration), 
including patient enrollment and a post -operative follow -up period 
of 24 months per subject.  
 
Primary Outcome 
Measures :  Fusion : evaluated radiographically (by AP, lateral and 
flexion/extension X -Rays) at 24 months ; fusion is defined as:    
a. Angular motion ˂ 3º; AND   
b. Translational motion ˂ 3 mm; AND  
c. Presence of continuous bridging bone between the 
involved motion segment, i.e.: 
 Presence of interbody (between endplates) 
bridging bone and absence of radiolucency > 
50%; OR 
 Presence of left posterolateral bridging bone; 
OR 
 Presence of left posterolateral bridging bone.  
 Pain (low back and/or leg/s): assessed based on Visual 
Analogue Scale (VAS), at 24 months;  defined as an 
improvement  of at least 20 mm on a 100 mm VAS from the 
baseline level . 
 Function : assessed by Oswestry Disability Index (ODI), at 24 
months;  defined as an improvement of at least 15 points from 
the baseline level . 
 Safety:  
 No worsening in neurological status (motor, sensory, 
reflex, straight leg raising, and tenderness assessments) 
and no new permanent neurological deficits present for 
at least 2 successive visits at or beyond 6 months (out 
to 24 months) ;  
 Absence of device -related serious adverse events 
through 24 months;  
 Absence of subsequent surgical interventions at the 
index level through 24 months.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 8 of 117  
 
Secondary Outcome 
Measures :  Subject's Overall Well -Being : assessed by 12 -Item Short 
Form Health Survey (SF -12), at 24 months ; 
 Satisfaction : assessed based on VAS, at 24  months;  
 Donor Site Pain : asses sed based on VAS, at 24  months;  
 Operation time ; 
 Blood loss . 
 
 Follow -Up: Radiographic ( AP, lateral and flexion/extension  X-Rays ) and clinical 
evaluations .  
Follow -up sessions at 6 weeks, 3 months, 6 months , 12 months , and 
24 months postoperatively, and then annually, until the last patient 
has completed 2 -year follow -up.. 
 
Inclusion Criteria:  1. Subject  has degenerative disc disease (DDD) at  one level, from 
L2 to S1 vertebrae , with up to Grade I spondylolisthesis.   
DDD is defined as back pain and/or radicular leg pain with 
degeneration of the disc confirmed by patient history, 
radiographic studies, and physical examination, with one or 
more of the following factors ( as measured radiographically, 
either by CT, MRI or plain film, myelography, discography, 
etc.): 
 osteophyte formation of facet joints or vertebral endplates;  
 decreased disc height, on average by > 2 mm;   
 scarring/thickening of ligamentum flavum, annulus 
fibrosis, or facet joint capsule;  
 herniated nucleus pulposus;  
 facet joint degeneration/changes;  
 vacuum phenomenon.  
2. Subject is candidate for single level intervertebral fusion, with 
or without posterolateral fusion, with implantation of 
intervertebral body fusion device and supplemental fixation.  
3. Subject age is between 21 – 72 years, and subject is skeletally 
mature .  
4. Pre-operative low back and/or leg/s pain (debilitating pain that 
causes  a significant disturbance of the routine daily physical 
activities) ≥ 40 mm on a 100 mm Visual Analogue Scale (VAS).   
5. Pre-operative Oswestry Disability Index (ODI) score ≥ 40 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 9 of 117  
 
percenta ge-point, indicating at least moderate disability 
(interpreted as moderate /severe disability).  
6. Low back and/or leg/ s pain is unresponsive to prior non -surgical 
management for a minimum of six months. Non -operative 
treatment includes pain medication, physic al therapy and/or 
injections.  
7. Patient must understand and sign the informed consent.  
8. Patient is willing and able to meet the proposed follow -up 
schedule including return to follow -up visits and complete 
necessary study paperwork.  
9. Patient is willing and able to follow the postoperative 
management  program.   
 
Exclusion  Criteria : 1. Previous fusion or fusion attempts, including anterior fusion or 
posterolateral fusion, at the index level.  
2. Previous fusion or fusion attempts at the adjacent levels.  
3. Prior decompression procedures that include removal of soft and 
bone tissue at the index  or adjacent levels . 
4. Patient is not skeletally mature.  
5. Degenerative spondylolisthesis greater than Grade I.  
6. Spinal instability at the index level with ≥ 3 mm translation 
and/or ≥ 5 degrees angulation. Determination of instability will 
be assessed using flexion/extension lateral view radiographs . 
7. Isthmic spondylolisthesis.   
8. Radiographically confirmed moderate or severe spinal stenosis 
with associated neurogenic claudication.  
Definitions:  
 Radiographically confirmed moderate/severe stenosis  is 
defined as reduction of ˃50% of central and/or foraminal 
canal diameter compared to the adjacent uninvolved 
levels.  
 Neurogenic claudication  is leg, groin, or buttock pain 
and/or numbness that worsens with walking or erect 
posture and is relieved with flexion of the spine.  
9. Systemic infection or infection at the site of surgery.  
10. Metabolic bone disease, such as osteopenia, osteoporosis, and 
osteomalacia. A screening Questionnaire for osteoporosis, 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 10 of 117  
 
SCORE (Simple Calculated Osteoporosis Risk Estimation), will 
be used to screen patients who require a DEXA bone mineral 
density measurement. If DEXA is required, exclusion will be 
defined as measured T -score less than or equal to -2.5 (WHO 
definition).  
11. History of Paget’s disease or other bone pathologies, whether 
acquired or congenital, including renal osteodystrophy, 
untreated or uncontrolled hyperthyroidism, hypothyroidism, or 
hyperparathyroidism, Ehrl ers-Danlos -syndrome, osteogenesis 
imperfecta, achondroplasia, tuberculosis.  
12. Personal and/or familial history NF2, and/or spinal tumor.  
13. Ankylosing spondylitis.  
14. Diffuse idiopathic skeletal hyperostosis (DISH) syndrome.  
15. Active hepatitis (viral or serum) or H IV positive, renal failure, 
systemic lupus erythematosus, or any other significant medical 
conditions which would substantially increase the risk of 
surgery.  
16. Immune deficiency disease.   
17. Patient is receiving immunosuppressive or long -term steroid 
therapy.  
18. Active malignancy or other significant medical comorbidities.  
19. All concomitant diseases that can jeopardize the functioning and 
success of the patient.  
20. Allergy to any component of the investigational device, 
including carbon fiber -reinforced polyetherether ketone (CFR -
PEEK), titanium, and tantalum.  
21. Pregnancy, or female subject interested in become pregnant 
during the duration of the study.  
22. Current chemical dependency  (e.g., drug and/or alcohol abuse, 
according to DSM -V definition), as well as those with a h istory 
of such abuse . 
23. Uncontrolled d epression, psychosis, or other symptoms of a 
mental disorder that, in the investigator’s opinion, likely would 
make the subject unable to comply with the study procedures 
and could affect the study outcome.  
24. Treatment wit h drugs that may interfere with bone metabolism, 
such as glucocorticosteroids, calcitonin, bisphosphonates, bone 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 11 of 117  
 
therapeutic doses of fluoride, bone therapeutic doses of vitamin 
D or vitamin D metabolites, and treatment by chemotherapy.  
25. Morbid obesity (BM I ≥ 40).  
26. Current smokers (including 3 months prior to surgery).  
27. Scoliosis, Cobb angle greater than 11°.  
28. Vertebral fractures.  
29. Severe muscular, neural or vascular diseases that endanger the 
spinal column.  
30. Missing bone structures, due to severely deformed a natomy or 
congenital anomalies, which make good anchorage of the 
implant impossible.  
31. Paralysis.  
32. Current use of other investigational drug or device.  
33. The patient is involved in a worker’s compensation case or 
spine -related litigation.  
34. The patient is a pris oner.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 12 of 117  
 
3. INTRODUCTION  
Chronic low back pain (CLBP) occurs in up to 60% - 80% of the adult population in the 
USA, with up to 5% experiencing this pain annually  1, 2, 3. CLBP is a leading cause of 
morbidity and disability, thus constituting a leading health and economic challenge. It has 
been recognized that in some cases axial  low back pain is secondary to dehydration and 
biochemical changes of the intervertebral dis c. A d egenerative cascade  has been suggested  
by Kirkaldy -Willis  4, describing the pathophysiologic process as it affects the lumbar spine 
and individual motion segments.  The term “d egenerative dis c disease”  (DDD ) has been 
coined for this entity. It should be noted, that d egenerative changes may or may not be 
associated with clinical sym ptoms . Vast scientific reports have described degenerative 
imaging findings in asymptomatic population 5, 6. The high prevalence of the degenerative 
process in both symptomatic and asymptomatic subjects limits the ability to correlate 
anatomic derangement and clinical symptoms 7. Also, there is l ack of consensus regarding 
the terminology and standardized clinical definition of DDD.  
 
Most cases of low back pain are self -limiting in that only 7% of the patients have 
symptoms that persist beyond two weeks, wit h only 1% of those requiring prolonged 
treatment and even fewer eventually requiring surgical intervention 8. The primary 
                                                 
1 Guo HR, Tanaka S, Halperin WE, Cameron LL. Back pain prevalence in US industry and estimates of lost 
workdays. Am J Public Health  1999; 89(7):1029 -1035. 
2 Mazroa AL, Mohammad A . Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and 
injuries 1990 -2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet  
2012;380(9859):2163 -96.  
3 Andersson GB  Epidemiological features of chronic low -back pa in. Andersson GB. Lancet  1999 Aug  
14;354(9178):581 -585.  
4 Kirkaldy -Willis WH, Wedge JH, Yong -Hing KJR. Pathology and pathogenesis of lumbar spondylosis and  
stenosis. Spine  1978;3:319 -28. 
5 Roh JS, Teng AL, Yoo JU, et al.  Degenerative  disorders of the lu mbar and cervical spine. Orthop Clin 
North Am  2005;36:255 –262. 
6 Dickerman RD, Zigler JE. Discogenic back pain. In: Spivak JM, Connolly PJ, eds. Orthopaedic Knowledge 
Update Spine 3. Rosemont, IL: American Academy of Orthopaedic Surgeons; 2006:319 –329. 
7 Modic MT, Ross JS. Lumbar degenerative disk disease. Radiology  2007;  245: 43 -61. 
8 Report of the Quebec Task Force on Spinal Disorders. Scientific approach to the assessment and 
management of activity -related spinal disorders. A monograph for clinicians. Spine 1987 Sep;12 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 13 of 117  
 
treatment for the majority of pa tients with DDD is non -operative. A wide variety of non -
operative treatments are available including p hysical therapy (both active and passive 
modalities), medications (including analgesics, anti -inflammatories, muscle relaxants, and 
antidepressants), injections (both epidural and facet injections), patient education, 
chiropractic manipulation, traction, b racing, and acupuncture.  However, if symptoms 
persist and/or progress despite non -operative management (particularly to the point of 
significantly impacting quality of life and the ability of the patient to function), surgery 
becomes an option. It has been  recognized that surgery has favorable outcome for selected 
population that has failed non -operative treatment .  
 
The current surgical standard of care for treating lumbar degenerative disease includes 
interbody fusion (ALIF, PLIF, TLIF) , combined with pos terolateral arthrodesis and pedicle 
screw systems  fixation 9. Over the last few decades, posterior pedicle screws 
instrumentation have evolved and revolutionized surgical care of various spinal disorders. 
Presently, pedicle  screw systems are the workhorse of spinal instrumentation for the adult 
spine. Since their introduction in 1969, numerous advances in surgical and instrumentation 
techniques have been adopted, leading to continues progress in clinical outcomes 10.  
 
The evolution of biomaterials assigned for these systems contributed  to this progress. 
Titanium has gained wide popularity and has largely replaced conventional stainless steel. 
However, metallic implants possess several inherent shortcomings, including that metal 
alloys may severely degrade th e quality of images of  modern imaging techniques (CT and 
                                                                                                                                                     
(7Suppl):S1 -59. 
9  Zigler JE, Delamarter RB. Does 360° lumbar spinal fusion improve long -term clinical outcomes after 
failure of conservative treatment in patients with functionally disabling single -level degenerative lumbar 
disc disease? Results of 5 -year follow -up in 75 postoperative patients. Int J Spine Surg . 2013 Dec 1;7:e1 -
7. 
10  Gaines  RW Jr. The use of pedicle -screw internal fixation for the operative treatment of spinal disorders. J 
Bone Joint Surg Am . 2000 Oct;82 -A(10):1458 -76. 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 14 of 117  
 
MRI) due to metal -induced artifacts, and therefore may prevent accurate postoperative 
assessment of region of interest near the implants 11, 12, 13. 
Carbon fiber -reinforced -polyetheretherketone composite (CFR -PEEK) has been suggested 
to overcome these limitations. The potential advantages of this composite material include 
inherent radiolucency and MRI and CT compatibility, resulting in negligible impl ant-
induced artifacts, and superior fatigue life in compared to traditional implants. In addition, 
CFR -PEEK composites are biocompatible, and are rigid with structural stiffness equivalent 
to metallic biomaterials. All of those properties are ideal for spi nal surgical implants. CFR -
PEEK based spinal cages and other CFR -PEEK bone implants are cleared and in clinical 
use, and multiple studies reported their safety and effectiveness 14, 15.  
 
The aim of the current study is to evaluate the safety and effectivene ss of a novel CRF -
PEEK pedicle screw system, t he CarboClear Pedicle Screw System ("CarboClear System" ). 
This is a rigid, pedicle screw system, intended to provide immediate immobilizat ion and 
stabilization of the lumbar and/or sacral  spine  in DDD patients undergoing spinal fusion . 
The CarboClear System  comprises polyaxial pedicle screws, longitudinal rods, and locking 
elements. The implants are made of CFR -PEEK  with radiopaque markers. The threaded 
portion  of the pedicle screw s is encased within a thin  titanium shell. The design and 
dimensions of the implant components are similar to those of other, market -available 
pedicle screw systems. The implantation technique and the instrumentation used during the 
operation are also similar to those used for othe r, cleared,  pedicle screw systems.  
                                                 
11 Rutherford EE , Tarplett LJ , Davies EM , Harley JM , King LJ , Lumbar spine fusion and stabilization: 
hardware, techniques, and imaging appearances . Radiographics , 2007;27(6):1737 -1749. 
12 Romero -Muñoz  LM, Alfonso  M, Villas  C, Zubieta  JL, Effect of brightness in the evaluation of lumbar 
pedicular screws position: clinical study . Musculoskeletal Surgery , 2013;97(2): 159 -164. 
13  Stradiotti  P, Curti  A, Castellazzi  G,  Zerbi  A, Metal -related artifacts in instrumented spine. Techniques for 
reducing artifacts in CT and MRI: state of the art . Eur Spine J , 2009;18(1):102 –108. 
14  Kurtz SM, Devine JN . PEEK biomaterials in trauma, orthopedic, and spinal implants.  Biomaterials  2007  
Nov;28(32):4845 -69. Epub 2007 Aug 7.  
15  Vannabouathong C, Sprague S, Bhandari M , Li CS.  The Use of Carbon -Fiber -Reinforced (CFR) PEEK 
Material in Orthopedic Implants: A System atic Review. Clin Med Insights Arthritis Musculoskelet Disord . 
2015 Feb 23;8:33 -45. 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 15 of 117  
 
Pre-clinical testing indicates that biomechanical performance of the system is similar to that 
of titanium pedicle screw systems. In addition, the system is being clinically investigated 
outside the USA, with good interim  results.  
 
This study is designed to demonstrate the safety and effectiveness of the CarboClear 
System for lumbar /sacral  fusion requiring immediate, rigid stabilization of the spine.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 16 of 117  
 
4. DEVICE DESCRIPTION  
4.1 DEVICE INTENDED USE/INDICAT IONS FOR USE  
The CarboClear Pedicle Screw System is intended to provide rigid immobilization and 
stabilization of lumbar and/or sacral segments as an adjunct to fusion in patients with 
degenerative disc disease (DDD) at one level from L2 to S1, with up to Grade I 
spondylol isthesis. DDD is defined as back pain of discogenic origin with degeneration of 
the disc confirmed by history and radiographic studies. Patients should be skeletally mature 
and have at least six months of non -operative treatment.  
The CarboClear Pedicle Scr ew System is designed for use with intervertebral body fusion 
device and with autogenous and/or allogenic bone graft comprised of cancellous and/or 
corticocancellous bone graft.  
 
4.2 SYSTEM DESCRI PTION  
The CarboClear Pedicle Screw System  ("CarboClear System" ) is composed of implants in 
various dimensions, used to build a spinal construct;  and of a set of surgical instruments, 
intend ed to assist in the insertion and placement of the implants.  Each of these components 
is described below.  
 
4.2.1 IMPLANT DESCRIPTION  
CarboClear System  comprises polyaxial pedicle screws, longitudinal rods, and locking 
elements.  
The implants are made of carbon fiber -reinforced polyetheretherketone (CFR -PEEK)  with 
radiopaque markers . The threaded portion  of the pedicle screw s is encased wit hin a thin  
titanium shell.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 17 of 117  
 
4.2.1.1  Poly axial Pedicle Screws  
The polyaxial pedicle screws  comprise a spherical head enclosed within a housing ("tulip"), 
enabling screw positing in a variety of angles and facilitating connection of the rod. Both  
cannulated and non -cannulated screws are available. The cannulated screws include a 
lumen of 1.3 mm diameter, to enable their insertion into the bone over a guide wire.  
The screws are made of CFR -PEEK, and their threaded portion  as well distal tip are 
encased within a 0. 1 mm thickness shell, made of pure titanium (Grade I or II, per ASTM F 
67), so that  the screw portion that contacts the bone is made of titanium. The titanium shell 
is a sealed, non -porous, coating . It enable s screw visualiz ation  under ima ging, during screw 
introduction into the vertebra, as well as post -operatively . As the metal content in the screw 
is minimal, the metal -induced artifacts seen in CT/MRI imaging are minimal compared to 
all-metal pedicle screw systems.    
The Pedicle Screw is  depicted in Figure 1. Each  pedicle screw is provided to the user as a 
"pedicle screw assembly", together with a tulip -like component that surrounds the screw 
spherical head (refer also to Figure 2 below). The tulip, made of CFR -PEEK, includes  a 
tantalum w ire along  its perimeter, to allow its visualization under imaging . 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1: CarboClear System  - Pedicle Screw  Threaded 
Portion  
(Encased within 
Titanium Shell)  Spherical  Head   
(within Tulip)  
 
Tantalum  
 Marker   
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 18 of 117  
 
The pedicle screws are available in  diameter of 5.5 mm, 6.5 mm and 7.5 mm, in lengths 
ranging from 35 mm to 55 mm (depending on screw diameter ), in 5 mm increments.  
 
 
   
  
 
 
 
 
 
 
 
 
4.2.1.2  Rods 
Longitudinal rods, of 6.0 mm diameter, available in lengths ranging from 30 mm to 220 
mm. The rods are provided pre -cut, either straight or pre-contoured. The curved rods are 
provided with the following optional curvature radii: light curve - radius of 440 mm; 
moderate curve - radius of 240 mm; and prominent curve - radius of 120 mm).  
A tantalum wire  is incorporated along the long axis of the  CRF -PEEK rods , thus enabling 
their visualization under imaging.  
The curved and straight rods are depicted in Figure 3.  
 
 
 
  
 
 
Figure 3: CarboClear System  – Curved (Left) and Straight (Right) Rods  Figure 2: CarboClear System  - Pedicle Screw Assembly   
Screw Tulip  
Screw Thread  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 19 of 117  
 
4.2.1.3  Locking Element  
The component  is made of CRF -PEEK and comprises  a tantalum marker , to provide for its 
visualization under imaging .  
At its upper portion, the locking element includes a lumen to accommodate the rod. During 
operation, the lower portion  of the locking element  is positioned within the cavity of the 
screw tulip, above the screw spherical head. In order to lock the implant components, the 
lower portion of the locking element is pressed against the tulip using dedicated 
instrumentation.  
 
 
    
 
 
 
 
 
 
 
 
 
 
Prior to final locking, the physician may slide the locking elements along the rod, to locate 
them at a desired position, and afterwards to lock them at that position.  The locking 
elements may be provided already mounted over the rod, as depicted in Figure  5.  
  
 Figure 4: CarboClear System  – Locking Element  
  
Opening for the Rod  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 20 of 117  
 
 
 
 
 
 
 
4.2.1.4  Implant Assembly  
Once assembled and locked, the CarboClear  implant provides for a rigid construct, with no 
relative motion between its components. The construct (Figure 6 (standalone) and Figure 7 
(attached to a spinal model)) provides for immediate stabilization  and immobilization of the 
involved spinal segment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Figure 6: CarboClear System – Assembly of Implant Components  
 Figure 5: CarboClear  System  – Locking Elements Mounted on a Straight Rod (Right);   
and on  a Curved Rod (Left)  
  
 
 Locking Element  
 Rod 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 21 of 117  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 summarizes  the suggested implant components of the CarboClear System and their 
characteristics  (materials and dimensions) . Implant  dimensions are within the  range of 
dimensions seen in similar  pedicle screw systems available on the market .  
 
  Figure 7: CarboClear System – Assembly of Implant Components, Attached to A Spinal Model  
  

                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 22 of 117  
 
Table 1: CarboClear  System  – Implant Components  
Implant 
Component  Material  Thread  Diameter  
[mm]  Length  
[mm]  ROM  
[Degrees]  
Polyaxial Pedicle 
Screw  CFR -PEEK;  
Screw shank - CP Ti shell ; 
Tulip includes a Ta wire  
  5.5 * 35, 40, 45  40 
6.5 ** 35, 40, 45, 50  30 
7.5 ** 35, 40, 45, 50, 55  20 
Rod  
Straight  
CFR -PEEK, with Ta wire  6.0 30 – 120 
(5 mm steps)  - 
Rod  
Curved (Moderate ) / 
Curved  (Prominent ) 30 – 80 
(5 mm steps);  
90 – 200 
(10 mm steps)  - 
Rod  
Curved (Light ) 30 - 220 
(10 mm steps)  - 
Locking Element  CFR -PEEK, with Ta marker  - - - 
*   Provided non -cannulated  
** Provided either can nulated or non -cannulated  
 
4.2.2 SURGICAL INSTRUMENTS  
The instrumentation to be provided with CarboClear System is used for bone preparation 
and implant introduction and placement  (as well as for implant removal, if required) . 
The instruments  are, in general, multi -use surgical instrument s, made of metal (such as 
stainless steel complying with ASTM F 899  or ASTM F 138 ) and polymeric material ( e.g., 
PEEK and propylux).  They  are similar to instruments used with other market -available 
pedicle  screw systems, and to instruments supplied with ot her systems by the Company. 
Some accessories , such as guide wires,  may be provided for single use.  
 
The instrumentation for the CarboClear System  include s the following components:  
Pedicle Awl  
Used to gain access through the bone cortex 
into the pedicle.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 23 of 117  
 
 
Pedicle Probes  
Straight and curved , pointed  or blunt , pedicle 
probes, intended to  tunnel through the pedicle 
cancellous bone into the vertebral body.  
The probes include depth markings, to 
facilitate the assessment of pedicle screw 
appropriate length.   
 
Pedicle Feeler  
A ball -tipped device, used to verify  pedicle 
wall integrity prior to tapping. It is marked to 
assist in the assessment of pedicle screw 
length.  
 
1.5 mm Guide Wire   
A ball -tipped guide wire . May be used to 
maintain trajectory during tapping and 
reaming . 
 
1.1 mm Guide Wire   
May be used to maintain trajectory for the 
insertion of the cannulated pedicle screw.  
 
Bone Taps   
Cannulated taps , with diameter range of  4.5 - 
7.5 mm . Used with a dedicated handle, to 
prepare the pedicle screw canal. May be used 
over the  guide  wire.  The tap s are  marked to  
 
 
 
 
 
 
 
 
 
   
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 24 of 117  
 
assist in the assessment of pedicle screw 
length.  
 
Pedicle Surface Reamer  
May be used , if required, to ream the surface 
of the pedicle in order to allow 
accommodation of the pedicle screw  head and 
tulip. The reamer is cannulated to enable 
reaming over the guide wire.  
 
X-Ray Marker s 
May be used for radiographic verification of 
pathway positioning. Available in notched or 
smooth  options , to distinguish right or left 
placement and to assess screw length.  
The markers are used with a dedicated 
inserter.  
 
Pedicle Screw Screwdriver   
A dedicated screwdriver, intended for the 
insertion of the pedicle screw into the pedicle. 
It is cannulated and may be used over the 
guide wire.   
 
Tulip Adjusters  
Used in case adjusting  of the tulip orientation 
is required . 
 
   
  
X-Ray Marker, Left  X-Ray Marker, Right  
 
 

                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 25 of 117  
 
Rod Measuring Templates   
Straight and curved bendable rods, in several 
lengths, used to aid in selecting the  proper 
rod. May be used with the Rod Holding 
Forceps.  
 
Rod Holding Forceps  (& X -Ray Marker 
Inserter)  
May be u sed to securely hold the  rod for its 
placement and positioning within the implant 
construct.   
 
Rod & Locking  Elements Holder  
Used to securely hold the locking elements 
and the rod, for their placement and 
positioning within the implant construct.  
 
Rod Pusher   
Used to push the rod for its location in place , 
if required.  
  
Distractor  
Used to perform distraction, in case required .  
 
Persuader   
The persuader  may be used for partial 
locking.   
 
   
 
 
 
 
 
 

                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 26 of 117  
 
 
Locking Device  
Used to press the locking element against the 
screw's tulip, in order to lock the screw -rod 
construct at a desired angle.  
 
Disassembly  Device   
Used to open (disconnect) the locked rod -
screw construct, in case re -positing or 
removal of the implant  is required.  
The unlocker component is connected to the 
distal end of the Locking Device.   
 
Pedicle Screw Extractor  (for damage d 
screw)  
The screw extractor, assembled to the T -
handle, may be used i n case removal of a 
damaged ( e.g., broken) pedicle screw is 
required. The handle should be counter -
clockwise rotated, to remove the pedicle 
screw. The extractor is available in three 
dimensions, to comply with the different 
diameters of the pedicle screw . 
 
Additional surgical instruments, such as mallet may also be provided, to assist in the 
procedure, when required.  
  
 
Unlocker  
Component   
Pedicle Screw  
 
 
 
 
 
 
 Rod 
Ca
utio
n: 
In 
the 
U.S
.A., 
fed
eral 
law 
rest
rict
s 
this 
dev
ice 
to 
sale 
by 
or 
on 
the 
ord
er 
of a 
phy
sici
an. 
 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 27 of 117  
 
4.2.3 PRINCIPLES OF OPERATION  
The implant components of the CarboClear System are implanted in a similar manner to 
that used for the implantation of other pedicle screws systems available on the market, as 
an adjunct  to vertebrae fusion  procedure.  
 
A detailed operational procedure is described in the Surgical Technique ( Appendi x A).  
In short, the implants of the CarboClear System are introduced in a standard approach. 
Following preparation of the vertebral pedicles, the screws are inserted into the vertebral 
body via the pedicles. A rod with two or more locking elements  is then placed at each side 
over adjacent screws, to longitudinally connect them. The locking elements may slide along 
the rod, to be located at a desired position. Initial (partial) locking is conducted by pressing 
the locking element against the screw' tulip. At this stage, distraction may be performed, if 
required. Following confirmation of implant components position, a final, firm locking of 
the rod to the screws is performed using the locking  device.    
 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 28 of 117  
 
5. INVESTIGATIONAL PLAN  
5.1      PURPOSE  
The purpose of this clinical investigation is to demonstrate the safety and effectiveness of 
the CarboClear Pedicle Screw System (" CarboClear System"), for skeletally mature DDD 
patients undergoing one level spinal fusion , in combination  with interbody fus ion device, 
and requiring immediate, rigid, posterior spinal stabilization of the lumbar and /or sacral 
spine .  
  
5.1.1    OUTCOME MEASURES  
The following outcome measures will be evaluated in subjects participating in the study:  
Primary Effectiveness and Safety Outcome Measures :   
 Fusion : evaluated radiographically (by AP, lateral and flexion/extension X -Rays) at 
24 months ; fusion is defined as:    
a. Angular motion ˂ 3º 16; AND   
b. Translational motion ˂ 3 mm; AND  
c. Presence of continuous bridging bone between the  involved motion 
segment 17, i.e.: 
 Presence of interbody (between endplates) bridging bone and 
absence of radiolucency > 50%; OR 
 Presence of left posterolateral 18 bridging bone; OR 
 Presence of left posterolateral 18 bridging bone.  
                                                 
16  In addition to angular motion of 3 degrees, the Company will provide fusion data and analysis using a 
threshold of 5° of angular motion. Additional information is provided in Section 3.10.1 .  
17  The definition above calls for “continuous” bridging bone (wi th or without trabeculation). That is, solid 
bridging with no intervening fractures or discontinuities. Conventional plain film imaging rarely supports 
visualization of trabeculae.  
18  Right posterolateral - between the right facets, pedicle and/or transver se processes; left posterolateral - 
between the left facets, pedicle and/or transverse processes . 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 29 of 117  
 
 Pain (low back and/or leg/s): assessed based on Visual Analogue Scale (VAS), at 
24 months ; defined as an improvement  of at least 20 mm on a 100 mm VAS from 
the baseline level . 
 Function : assessed by Oswestry Disability Index (ODI), at 24 months; defined as 
an improvement of at least 15 points from the baseline level . 
 Safety :  
 No worsening in neurological status (motor, sensory, reflex, straight leg 
raising, and tenderness assessments) and no new permanent neurological 
deficits present for at least 2 successive visits at or beyon d 6 months (out to 
24 months) ; 
 Absence of device -related  serious adverse events through 24 months.  
 Absence of subsequent surgical interventions at the index level through  24 
months.  
  
Secondary Outcome Measures:   
 Subject's Overall Well -Being : assessed by 12 -Item Short Form Health Survey (SF -
12), at 24 months;  
 Satisfaction : assessed based on VAS, at 24 months;  
 Donor Site Pain : assessed based on VAS, at 24 months;  
 Operation time ; 
 Blood loss . 
 
5.2      STUDY DESIGN  
A prospective, multi -center, confirmatory, single arm, study.   
A total of up to 55 subjects with DDD at one level from L2 to S1, who have failed to 
improve with conservative treatment for  at least six months prior to enrollment, will 
participate in this stu dy. At least 30 patients  will be enrolled at US sites with the rest being 
enrolled in sites outside the US.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 30 of 117  
 
All patients will be implanted with the investigational  device and an FDA cleared PEEK 
interbody fusion device (Medtronic's Capstone PEEK Spinal Sy stem (K073291, K103731, 
and more); or Medtronic's Crescent PEEK Spinal System (K094025, K133216, and more)), 
using PLIF or TLIF approach, and undergo interbody spinal fusion. According to the 
physician discretion, posterolateral spinal fusion may also be p erformed, using autogenic 
bone graft (from local and/or iliac crest bone) and/or allogenic bone graft comprised of 
cancellous and/or corticocancellous bone graft. As Medtronic's Capstone and Crescent 
Systems are cleared only with autogenous bone graft, onl y autogenous bone graft will be 
packed into the cage. In case posterolateral fusion is also conducted, either autogenous 
bone graft or allogenic bone graft, as detailed above, may be used at this location.   
 
Pre-clinical data (bench testing), as described in the Investigator Brochure , demonstrated 
equivalency to cleared, rigid, metal, pedicle screw systems with similar intended use, both 
in terms of test results values and tests failure modes. In addition, clinical data regarding 
the use of the subject device, which is currently avail able from an on -going, out -of-the-US 
(OUS), multi -center study, and is summarized in the Investigator Brochure , also supports 
the effective and safe use of the investigational device. The discussed confirmatory clinical 
study is designed to further support  the safety and effectiveness of the CarboClear System.  
 
The results of the suggested study will be evaluated in relation to historical -based data, 
derived from the literature and described in Section 5.2.1.  
Comparison to retrospective data from the literature regarding metal pedicle screw systems  
used in conjunction with interbody fusion device will be made in terms of efficacy and 
safety.  
Individual patient success ( i.e., overall success) is defined as a composite endpoint. A 
patient will be consid ered a "success" if all primary effectiveness and safety outcome 
measures  listed above  are met. As detailed  later in this document , the statistical analyses of 
the suggested study will be descriptive in nature.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 31 of 117  
 
During the clinical investigation, the patie nts will be evaluated preoperatively (baseline), 
intraoperatively, at discharge, and postoperatively at 6 weeks, 3 months, 6 months, 12 
months and 24 months, and then annually, until the last patient completed 2 -year follow -up. 
Radiographic endpoints will be evaluated by two independent reviewers  at an imaging  core 
laboratory (Medical Metrics, Inc., Texas).  In the case of a disagreement between the two 
radiographic assessors, a third independent reviewer  will evaluate the radiographic images 
to adjudicate the findings. In addition, a CT scan will be acquired for subjects in which 
bridging bone status could not be determined form X -Rays, at each time point starting at 6 
months post -operatively.  
 
At each ev aluation time point, as applicable, the primary and secondary endpoints shall be 
evaluated (e.g., pain and function evaluations based on patient questionnaires shall be 
performed pre -operatively and starting at 6 -week follow -up visit; fusion assessment wil l be 
made starting at 6 -month). Complications and adverse events will be evaluated at each 
follow -up visits and over the course of the clinical trial. Detailed evaluation schedule is 
provided in Table 8 . 
 
5.2.1    LITERATURE CONTROL  
In order to identify stu dies for the literature control, a poly -phasic approach  was used:  
First, Table 6 of the FDA Executive Summary,  Prepared for the May 22, 2013 Meeting of 
the Orthopaedic and Rehabilitation Devices Panel of the Medical Devices Advisory 
Committe e, 2013 – Classification Discussion, Pedicle Screw Spinal Systems (Certain Uses 
– Class III Indications for Use ) ("FDA Executive Summary")  was used for extracting 
articles believed to have valid scientific evidence.  
The FDA Executive Summary  was reviewed. This docum ent includes a survey of literature 
aimed at establishing the safety and effectiveness of pedicle fixation systems as an adjunct 
to lumbar fusion for treatment of DDD patients. Table 6 of the said document 
(“Effectiveness Data for Posterior Pedicle Screw S pinal Systems for Class III Degenerative 
Indications ”) outlines key manuscripts identified by the Agency. All manuscripts reported 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 32 of 117  
 
in that table were extracted and carefully reviewed. Of these, prospective studies which 
focused on circumferential lumbar fu sion and pedicle screw fixation  or posterolateral 
fusion with pedicle screw fixation  for DDD patients , and which provide, at a minimum, 
fusion definition and fusion rate results, were selected fo r the review. Thus, re trospective 
studies presented in Table 6 (e.g., Acosta , Barnes  and Al-Masry ), and studies that did not 
report fusion definition and /or fusion results ( e.g., Glassman ), were excluded. Where 
applicable, both arms of randomized studies were captured for the literature control.  
Next, a computerized  search of the National Library of Medicine MEDLINE database 
utilizing the online search engine PubMed 19 was carried out, to cross -reference these 
results.  
The first search was carried out  during November -December 2014 , and was 
complemented  by a second sea rch during April -May 2015.  
The following search terms were utilized: "fusion" [Title/Abstract], OR “arthrodesis” 
[Title/Abstract], OR “Interbody” [Title/Abstract], OR "Posterolateral" [Title/Abstract];  
AND "lumbar" [Title/Abstract], OR "lumbosacral" [Titl e/Abstract]; AND “degenerative 
disc disease” [Title/Abstract], OR “disc degeneration” [Title/Abstract], OR "DDD" 
[Title/Abstract], OR "spondylosis" [Title/Abstract], OR “back pain” [Title/Abstract].  
The searches were limited to articles published in "Engli sh" [Language], “Humans” 
[Medical Subject Headings], NOT “case report” [Title], NOT "cadaver" [Title] OR 
"anatomical" [Title], NOT "children" [Title] OR "adolescent" [Title], NOT kinematic 
[Title/Abstract] OR “finite element” [Title/Abstract], from April 1 997 to 2015.  
A total of 3,990 reports  were obtained . 
 
Eleven eligible studies were selected for the analysis, according to the following criteria:  
(1) subjects were skeletally matured and had undergone spinal fusion for the lumbar 
and/or sacral spine;  
(2) the intervention included instrumented fusion  (interbody and/or posterolateral 
fusion), in at least one arm of the study;  
                                                 
19 http://www.ncbi.nlm.nih.gov/pubmed  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 33 of 117  
 
(3) indications were DDD with or without degenerative spondylolisthesis (up to Grade 
I);  
(4) the study reported at least fusion  definition a nd results of fusion rate;  
(5) patients were followed up to at least one year after surgery;  
(6) number of patients was at least 20;  
(7) manuscripts were given priority if published in high ranking journals and quoted in 
meta -analysis.  
(8) high level of evidence manuscri pts (I and II levels).  
The flowing manuscripts were selected:  
1. Fritzell P, Ha¨gg O, Wessberg P, Nordwall A, and the Swedish Lumbar Spine Study 
Group. Chronic Low Back Pain and  Fusion: A Comparison of Three Surgical 
Techniques. A Prospective Multicenter Rand omized Study from the Swedish 
Lumbar Spine Study Group. Spine  2002;27(11):1131 –1141.  
2. Zigler J, Delamarter R, Spivak JM, Linovitz RJ, Danielson GO, Haider TT, 
Cammisa F, Zuchermann J, Balderston R, Kitchel S, Foley K, Watkins R, Bradford 
D, Yue J, Yuan H, H erkowitz H, Geiger D, Bendo J, Peppers T, Sachs B, Girardi F, 
Kropf M, Goldstein J. Results of the prospective, randomized, multicenter Food and 
Drug Administration investigational device exemption study of the ProDisc -L total 
disc replacement versus circu mferential fusion for the treatment of 1 -level 
degenerative disc disease. Spine  (Phila. Pa 1976) 2007 ;32:1155 -1162.  
3. Anjarwalla NK, Morcom RK, Fraser RD. Supplementary stabilization with anterior 
lumbar intervertebral fusion --a radiologic review. Spine  (Phila. Pa 1976) 
2006;31:1281 -1287.  
4. Christensen FB, Hansen ES, Eiskjær SP, Høy K, Helmig P, Neumann P, 
Niedermann B, Bu¨nger CE. Circumferential Lumbar Spinal Fusion with Brantigan 
Cage versus Posterolateral Fusion with Titanium Cotrel –Dubousset 
Instrumen tation. A Prospective, Randomized Clinical Study of 146 Patients. Spine  
2002;2(23):2674 –2683.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 34 of 117  
 
5. Brantigan JW, Steffee AD, Lewis ML, Quinn LM, Persenaire JM. Lumbar 
interbody fusion using the Brantigan I/F cage for posterior lumbar interbody fusion 
and the va riable pedicle screw placement system: two -year results from a Food and 
Drug Administration investigational device exemption clinical trial. Spine  (Phila. Pa 
1976) 2000;25:1437 -1446.  
6. Hackenberg L, Halm H, Bullmann V, Vieth V, Schneider M, Liljenqvist U. 
Transforaminal lumbar interbody fusion: a safe technique with satisfactory three to 
five year results. Eur. Spine J  2005;14:551 -558. 
7. Brox JI, Sorensen R, Friis A , Nygaard O, Indahl A, Keller A, Ingebrigtsen T, 
Eriksen HR, Holm I, Koller AK, Riise R, Reikeras  O. Randomized Clinical Trial of 
Lumbar Instrumented Fusion and Cognitive Intervention and Exercises in Patients 
with Chronic Low Back Pain and Disc Degeneration. Spine  2003;28:1913 -1921.  
8. Delamarter R, Zigler JE, Balderston RA, Cammisa FP, Goldstein JA, Sp ivak JM. 
Prospective, randomized, multicenter Food and Drug Administration investigational 
device exemption study of the ProDisc -L total disc replacement compared with 
circumferential arthrodesis for the treatment of two -level lumbar degenerative disc 
disease: results at twenty -four months. J Bone Joint Surg . Am. 2011;93:705 -715. 
9. Christensen FB, Hansen ES, Laursen L, Thomsen K, Bu¨nger CE. Long -Term 
Functional Outcome of Pedicle Screw Instrumentation as a Support for 
Posterolateral Spinal Fusion Randomized Clinical Study With a 5 -Year Follow -up 
Spine  2002;27(12):1269 –1277.  
10. Narayan P, Haid RW, Subach BR, Comey CH, Rodts GE . Effect of spinal disease 
on successful arthrodesis in lumbar pedicle screw fixation. J Neurosurg  Spine  
2002;97:277 –280. 
11. Arnold PM, Robbins S, Paullus W, Faust S, Holt R, McGuire R. Clinical outcomes 
of lumbar degenerative disc disease treated with posterior lumbar interbody fusion 
allograft spacer: a prospective, multicenter trial with 2 -year follow -up. Am. J 
Orthop . (Belle  Mead NJ.) 2009;38, E115 -E122.  
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 35 of 117  
 
Data from the studies was extracted from full text articles and is summarized in the tables 
presented in Appendix B, in accordance with the requirements of the " FDA Guidance 
Document for the Preparation of IDEs for Spinal S ystems; issued on January 13, 2000 ".   
It is noted, that where an article describes a randomized clinical trial (RCT), only the study 
arm/s regarding circumferential fusion and pedicle screw and/or posterolateral fusion with 
pedicle screw  was taken for the following analysis.  
Please note, that in order to prevent misinterpretation, whenever possible the text in the 
fields of the tables in Appendix B was copied from  the articles, to use the exact wording  
used by the authors.  
 
The following  paragraphs  display the results regarding fusion rate, pain (VAS), function 
(ODI), and safety (adverse events), as presented in the literature control manuscripts (and in 
the FDA Executive Summary).  
 
A. Fusion  
The following table summarizes the fusion rates , as described in ten of the 11 articles 
referenced above. One study ( Arnold ) was not included in the fusion analysis due to 
discrepancies in fusion rates reported in the article. Please see detailed explanation in 
Appendix B, page 65.   
 
A total of ten level  I and II studies ( 556 patients) reported radiographic fusion outcome for 
DDD patients who underwent circumferential lumbar arthrodesis with pedicle screws, or 
posterolateral fusion with pedicle screws, and are used as historical controls.  
Nine  of those t en studies reported fusion outcome for homogenous cohorts or sub -cohorts 
(i.e., stratified for DDD patients) using x -ray methods and are therefore analogous to the 
subject IDE.   
In four studies ( Brantigan, Christensen , Christensen  II and Brox ), subgroup st ratification 
for single - and double level was not provided for fusion outcome parameter. One study 
(Delamarter ) report fusion rates for two level surgery DDD cohort.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 36 of 117  
 
In one study ( Hackenberg ), the results refer to a mixed cohort (DDD and isthmic 
spondyloli sthesis). Nevertheless, most of the patients were DDD patients, and as the non -
stratified fusion rate is similar to studies evaluating only DDD patients, it is believed the 
results of these studies are appropriate to be included in the control group as wel l. 
Therefore, th is stud y can also be included when determining the control fusion rate.  
Several of the studies evaluated fusion using tools and definitions less rigorous than those 
suggested for the proposed IDE study ( e.g., without flexion -extension radio graphs, and thus 
with no motion assessment). Therefore, the reported fusion rates of those articles may be 
regarded as worst case for the purpose of comparison. On the other hand, one study 
(Anjarwalla ) used thin cut CT to evaluate fusion, which is expecte d to yield a slightly 
lower fusion rate. Although the proposed study uses radiographs to assess fusion, both 
studies use x -rays to assess fusion. Therefore, the slight difference in imaging modalities 
does not preclude using the results of the study when d etermining the control fusion rate.  
Please note, that the ten studies utilized autogenous bone graft (mainly iliac crest bone 
graft), which is associated with higher fusion rates than allograft.  
Overall, the compilation of these ten articles, reporting f usion results for a total of 556 
DDD patients, provides for reliable control group for comparison of fusion rate. It is 
emphasized that all of the mentioned studies were regarded as appropriate for the review of 
DDD patients in the FDA Executive Summary, a nd thus are reported in Table 6 of the said 
document.    
Seven of the ten  studies report fusion rates at two years, while two studies (Christensen  and 
Nrayan ) reports rates at one year. One study ( Christensen  II) reports fusion rate at both one 
and two years. Slightly h igher fusion rates are expected at two years as compared to one 
year. As the fusion rate of the subject device is assessed at one year, it is either analogous 
or worst -case compared to the liter ature control. Therefore, despite differences in time 
points, a valid comparison can be made.  
Fusion success rates reported in the ten manuscripts, and calculated weighted average of 
values, are presented in the tables below. The weighting factor is the number of patients in 
each study.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 37 of 117  
 
Table 2: Literature Control - Radiographic Fusion Outcome  
*  Results refer to several diagnoses. In addition, subgroup stratification for single - and double level (or more) is not provided for 
fusion outcome parameter.  
‡    Subgroup stratification for single - and double level (or more) is not provided for fusion outcome parameter.  
☼  The number of DDD patients available for radiographic evaluation is assumed to be 22. The authors report the number of operated 
patients (73) and their stratification to the following 3 sub -groups: 24 with primary degeneration; 25 with secondary 
degeneration; and 24 with isthmic spondylolisthesis. Of these 73 patients, radiographic evaluation was performed for 67 patients 
(no stratif ications to the 3 sub -groups). As the number of patients in each of the 3 sub -groups is similar, we arbitrary decided that 
2 patie nts in each group were not available for the radiographic evaluation.  
♦   The number of DDD patients available for radiographic evaluation is assumed to be 22. The authors report the number of operat ed 
patients (72) and their stratification to the followin g 3 sub -groups: 19 with primary degeneration; 27 with secondary 
degeneration; and 27 with isthmic spondylolisthesis. Of these 72 patients, radiographic evaluation was performed for 57 patie nts 
(no stratif ications to the 3 sub -groups). As the number of pati ents in each of the 3 sub -groups is similar, we arbitrary decided that 
5 patients in each group were not available for the radiographic evaluation.  
§     Per CT.  
♣    According to FDA Summary of Safety and effectiveness.  
As shown in the table, the fusion  rates reported in the literature control range from 77%  to 
97% . 
   Single Level   Double Level  Procedure  Diagnosis  Cohort Size  Fusion  
Nfused/Nchhort  Fusion  
Rate [%]  
Fritzell  
2002 (Arm I)  N24=43 N24=21 ALIF or PLIF  
+ PLF + PSS  DDD  N24=64 58 64 91 
2 years  
Fritzell  
2002 (Arm II)  N24=35 N24=27 PSF + PSS  DDD  N24=62 54 62 87 
2 years  
Zigler  
2007  N24=69 - ALIF + PLF  
+ PSS  DDD  N24=69 67 69 97 
2 years  
Anjarwalla  
2006  N24=14 N24=10 ALIF + PLF  
+ PSS  DDD  N24=24 21 24 88 § 
2 years  
Christensen  ‡ 
2002 (Arm I)  Cohort comprised 1 -2 level 
surgeries; data not stratified  ALIF + PLF  
+ PSS or facet 
joints screws  DDD  N12=22 
(only DDD  
patients) ☼ 19 22 86 
1 year  
Christensen  ‡  
2002 (Arm II)  Cohort comprised 1 -2 level 
surgeries; data not stratified  PLF + PSS  DDD  N12=22 
(only DDD  
patients ) ♦ 19 22 86 
1 year  
Brantigan ‡ 
2000  Cohort comprised 1 -3 level 
surgeries; data not stratified  PLIF + PLF  
+ PSS  DDD  N24=91 82 91 90 ♣ 
2 years  
Hackenberg *    
2005  N36=39 N36=11 (2-level)  
N36=2 (3 -level)  TLIF + PLF  
+ PSS  30 DDD +  
22 isthmic  
spondyloli -
sthesis  N36=52 
 46 52 89 
2 years  
Brox ‡  
2003  Cohort comprised 1 -2 level 
surgeries; data not stratified  PLF + PSS  DDD  N12=35 29 35 84 
2 years  
Delamarter  
2009  - N24=61 ALIF + PLF  
+ PSS  DDD  N24=61 47 61 77 
2 years  
Christensen II ‡  
2002  Cohort comprised 1 -2 level 
surgeries; data not stratified  PLF + PSS  DDD  N=20  15 20 77 
1 year  
Naryan  
1997  N 12=34  - PLF + PSS  DDD  N12=34 31 34 91 
1 year  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 38 of 117  
 
The following sections provide for calculation for the control group fusion rates.  
For dichotomy (binary) outcome parameters, the following formulas were used to compute 
weighed average and  standard deviation:  
 
𝑊𝑒𝑖𝑔 ℎ𝑡𝑒𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 =𝑛1𝑝1+𝑛2𝑝2…𝑛𝑋𝑝𝑋
𝑛1+𝑛2…𝑛𝑋 
𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒 =𝑛1𝑝1𝑞1+𝑛2𝑝2𝑞2…𝑛𝑋𝑝𝑋𝑞𝑋
(𝑛1+𝑛2…+𝑛𝑋)2  
SD= √𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒2  
 
Where:  
p = success probability (fusion)  
q = failure probability (1 -P) 
 
𝑊𝑒𝑖𝑔 ℎ𝑡𝑒𝑑 𝑎𝑣𝑒𝑟𝑎𝑔𝑒 : 
=0.8779  
 
Standard deviation : 
= 0.0136  
Table 3: Literature Control - Average Fusion R ate 
 
To conclude, t he average fusion rate for the control group  is 87.79 % ± 1.36% . 
 Range  SD Weighted 
Average  1 or 2 
Level  Double 
Level  Single 
Level  Number of 
Patients  Number of  
Manuscripts  
97% 77% 1.36%  87.79%  127 195 234 488/556  10 
(a total of 12 
study arms)  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 39 of 117  
 
A recently published systematic literature review, which analyzed published literature to 
evaluate the efficacy of lumbar arthrodesis for DDD patients 20, reported " As a whole, these 
12 studies including 1420 fusion patients showed…., the fusion rate was 89.3%  (95% CI, 
84.4–94.2)" [emphasis added ]. This correlates with the above values.  
 
It should be stressed that part of the studies reported in the literature used less stringent 
definitions of fusion than those used in various IDE studies for lumbar fusio n, including the 
suggested IDE. For example, fusion rate of 74.6% was reported for the control group 
(Silhouette Spinal Fixation System) of the Dynesys Spinal System (Zimmer Spine) 
(P070031), and a fusion rate of 88.1% was reported for the control group (L T-CAGE 
Lumbar Tapered Fusion Device filled with ICBG) in P000058. Use in less stringent fusion 
definitions results in the relatively higher fusion rates reported in the literature. Further, per 
FDA’s recommendations, the definition of the angular motion in  the proposed IDE is even 
more rigorous ( i.e. 3° versus  5°) than the fusion definition of previous IDE studies.    
 
B.  ODI  
The following table s summarize  the ODI results , as described in the articles referenced 
above.  
The ODI (also known as the Oswestry Low Back Pain Disability Questionnaire) is a 
validated tool used to measure a patient's level of pain and functional disability. The test is 
considered the ‘gold standard’ of low back functional outcome tools 21. Past IDE studies 
success criterion required 15 -point improvement.  
 
A total of five level I and II studies (321 patients) from the control group reported the 
outcome of the Oswestry Disability Index  (ODI) for DDD patients who underwent lumbar 
arthrodesis with pedicle screws, and are used as historical c ontrols.   
                                                 
20   Phillips FM1, Slosar PJ, Youssef JA, Andersson G, Papatheofanis F.Spine (Phila Pa 1976). Lumbar Spine 
Fusion For Chronic Low Back Pain Due TO Degenerative Disc Disease: A Systematic Review. Spine  
2013;38(7):E409 -422. 
21   Fairbank JC, Pynsent PB. The Oswest ry Disability Index. Spine 2000 Nov 15;25(22):2940 -52. 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 40 of 117  
 
One study ( Zigler ) reported outcome for homogenous single level DDD cohort and is, 
therefore, directly comparable to the proposed IDE study. In three studies ( Fritzell, 
Hackenberg and Brox ), subgroup stratification for single - and double level D DD was not 
provided for ODI outcome parameter (please note, that Hackenberg  et al.  provide ODI 
results stratification for one/two -level for all subjects ( a total of 30 DDD patients and 22 
isthmic spondylolisthesis patients ); the overall ODI improvement is relatively similar for 
patients undergoing one - or 2 -level surgery). Delamarter  reported outcome for 
homogenous 2 -level DDD cohort. Overall, the final ODI value for all five studies is similar, 
suggesting that the differen ces in patient population do not preclude their pooling to enable 
a general comparison between the literature control and IDE study group.  
 
Results from three studies ( Zigler, Hackenberg  and Delamarter ) that evaluated ODI at one 
and two -year follow -up visi ts suggest that the number of patients that experienced a 
clinically meaningful change in ODI does not change significantly from one to two years, 
allowing pooling of both one and two year results.  
 
ODI outcome reported in the five manuscripts, and calcula ted weighted average of values, 
are presented in the tables below. The weighting factor was the number of patients in each 
study.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 41 of 117  
 
 
Table 4: Literature Control - Oswestrey Disability Index (ODI) Outcome  
 Single  
Level  Double 
Level  Procedure  Diagnosis  Cohort 
Size ODI 
Baseline  ODI 
12 Months  ODI 
24  Months  Improvement (Δ)  
(ODI bl-ODI last f. u.) % Improvement  
(Δ ODI / ODI bl) 
Fritzell  
2002 (Arm I)  N24=43 *  N24=21 *  ALIF or PLIF  
+ PLF + PSS  DDD  N24=65*  47.3 ± 10.9  - 38.5 ± 18.9  8.8 (19%)  
Fritzell  
2002 (Arm 
II) N24=35♦ N24=27 ♦ PSF + PSS  DDD  N24=59 ♦ 48.4 ± 11.6  - 33.6 ± 17.9  14.8 (30%)  
Zigler  
2007 N24=71 - ALIF + PLF  
+ PSS  DDD  N24=71 62.7 ± 10.3  40.7 39.8 ±  24.3  22.9 (37%)  
Hackenberg 
2005 No level stratification  TLIF +  PLF  
+ PSS  DDD  N36=30 58.4 ± 18.4  37.5 ± 19.3  37.0 ± 24.8  21.4 (37%)  
Delamarter  
2009 - N24=61 ALIF + PLF  
+ PSS  DDD  N24=61 64.8 ± 9.5  41.1 ± 23.0  38.7 ± 24.1  26.1 (40%)  
Brox  
2003 No level stratification  PLF + PSS  DDD  N12=35 42.0 ± 11.0  26.4 ± 16.4  - 15.6 (37%)  
 
*  The ODI evaluation was conducted for 65 patients, however the stratification to one and two -level was given to 64 patients that were radiographically evaluated.  
♦   The ODI evaluation was conducted for 59 patients, however the stratification to one and two -level was given to 62 patients that were radiographically evaluated.   
 
 
 
 
 
 
 
 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 42 of 117  
 
Table 5: Literature Control - ODI Reference Results  
 
As can be seen, the similar values were reported for one - and 2 -level and for one - and two years, 
justifying the pooling of the results.  
 
In addition, the recently published systematic literature review (Phillips et al.) mentioned above 
analyzed published literature to evaluate the efficacy of lumbar arthrodesis for DDD patients, 
reported " As a whole, these 12 studies including 1420 fusion patients showed a weighted average 
improvement in ODI function of 24.7 ± 6.2/100 (47.2% change; 95% CI, 41.3 –53.1) " [emphasis 
added ]. This correlates with the values  listed in the tables.  
  Points 
Range  Number of Manuscript s Number of 
Patients  Weighted 
Average  
12m Δ Improvement 
(single level)  22.0  1 71 22.0 
24m Δ Improvement 
(single level)  22.9  1 71 22.9 
12m Δ Improvement 
(double level)  23.7 1 61 23.7 
24m Δ Improvement 
(double level)  26.1 1 61 26.1 
12m Δ Improvement  
(1 & 2 levels  ) 20.9 – 
23.7 4 197 23.4 
24m Δ Improvement  
(1 & 2 levels  ) 8.8 - 26.1 4 
(total of 5 study arms)  286 18.5 
Range  Weighted Average 
Improvement (%)  Weighted Average 
Improvement (Δ)  Number of 
Patients  Number of  
Manuscripts  
26.1 
(40%)  8.8 
(19%)  32.63%  18.22  321 5 
(a total of  
6 study arms)  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 43 of 117  
 
C. VAS Pain  
The following table summarizes the VAS (pain) results , as described in the articles referenced 
above.  
 
A total of five level I & II studies (321 patients ) from the control group reported pain outcome 
for DDD patients who underwent circumferential lumbar arthrodesis with pedicle screws, and 
are used as historical controls.  
 
The Visual Analog Scale (VAS) for Pain is a unidimensional measure of pain intensity, which 
has been widely used in diverse adult populations 22. It is a continuous scale comprised of a 
horizontal visual analog scale of 100 mm length. It is anchored by two verbal descriptors (No 
Pain and Severe Pain). Values here refer to back pain as VAS leg pain is reported in only one 
study (Fritzell ). Please note that also in Frizell study the back pain was the dominant pain 
component (compared to leg pain).  
 
One study ( Zigler ) reported VAS pain outcome for homogenous single level DDD cohort and 
was therefore analogous to the proposed IDE study. In the three studies ( Fritzell and Hackenberg  
and Brox ), subgroup stratification for single - and double level was not provided for VAS pain 
outcome parameter . Please note, that Hackenberg  et al provided VAS (pain) results stratification  
for one/two -level for all subjects ( a total of 30 DDD patients and 22 isthmic spondylolisthesis 
patients ); the overall VAS improvement is relatively similar for patients undergoing one - or 2-
level surgery). Overall, the final VAS score for most of the stu dies is similar, suggesting that the 
differences in patient population do not preclude their pooling to enable a general comparison 
between the literature control and IDE study group.  
 
 
                                                 
22  Mc Cormack HM, Horne DJ, Sheather S. Clinical applications of visual analogue scales: a critical review. 
Psychol Med  1988;18:1007 –1019.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 44 of 117  
 
As can be seen in the table below, VAS improvement results for the sam e patients at 12 months 
and 24 months postoperatively are very similar and results can be pooled from one to two years.  
 
VAS pain outcome reported in the five manuscripts and calculated weighted average of values 
are presented below. The weighting factor w as the number of patients in each study. Where 
applicable ( Hackenberg ), VAS score results were converted to a 100 -point score, for consistent 
interpretation.  
 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 45 of 117  
 
 
Table 6: Literature Control - Visual Analogue Scale (VAS) Outcome  
 
 Single  
Level  Double 
Level  Procedure  Diagnosis  Cohort 
Size VAS 
Baseline  VAS 
12 m  VAS 
24 m  Improvement (Δ)  
(VASI bl-VAS last f.u.) % Improvement  
(Δ VAS /VAS bl) 
Fritzell  
2002 (Arm I)  N24=43*  N24=21*  ALIF or PLIF  
+ PLF + PSS  DDD  N24=65*  65.6 ± 15.2  - 45.7 ± 26.7  19.9 (30%)  
Fritzell  
2002 (Arm 
II) N24=35♦ N24=27 ♦ PSF + PSS  DDD  N24=59 ♦ 63.3 ± 13.3  - 40.4 ± 23.9  22.9 (36%)  
Zigler  
2007 N24=71 - ALIF + PLF  
+ PSS  DDD  N24=71 75 ± 14.6  42 ± 28  43 ± 31.6  32 (43%)  
Hackenberg 
2005 No level 
stratification  TLIF +  PLF  
+ PSS  DDD  N36=30 83 ± 26  45 ± 23  48 ± 28  35 (42%)  
Delamarter  
2009 - N24=61 ALIF + PLF  
+ PSS  DDD  N24=61 74.7 ± 13.6  40.3 ± 27.9  38.4 ± 29.8  36.3 (49%)  
Brox  
2003 No level 
stratification  PLF + PSS  DDD  N12=35 62.1 ± 14.5  39.4 ± 25.5  - 22.7 (37%)  
 
*  The ODI evaluation was conducted for 65 patients, however the stratification to one  and two -level was given to 64 patients that were radiographically 
evaluated.  
♦  The ODI evaluation was conducted for 59 patients, however the stratification to one and two -level was given to 62 patients that were radiographically 
evaluated.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 46 of 117  
 
Table 7: Literature Control - VAS Reference Results  
 
 
As can be seen, the overall patient population had a VAS improvement of around 30 points.  
In addition , similar values were reported for one - and 2 -level and for one - and two years, 
justifying the pooling of the results.  
 
 
In addition, Phillips et al . published recently systematic literature review, which analyzed 
published literature to evaluate the efficacy of lumbar arthrodesis for DDD patients, and 
reported that " As a whole, these 12 studies including 1420 fusion patient s showed a weighted 
average improvement in back pain of 36.5 ± 17.2/100 points (43.3% change; 95% CI, 31.5 –
55.1) ." 
    
 
  Point  
Range  Number of 
Manuscript s Number of 
Patients  Weighted 
Average  
12m Δ Improvement 
(single level)  33  1 71 33  
24m Δ Improvement 
(single level)  32  1 71 32  
12m Δ Improvement 
(double level)  34.4 1 61 34.4  
24m Δ Improvement 
(double level)  36.3 1 61 36.3  
12m Δ Improvement  
(1 & 2 levels  ) 22.7 - 38 4 197 32.4 
24m Δ Improvement  
(1 & 2 levels  ) 19.9 – 36.3 4 
(total of 5 study arms)  286 28.6 
Range  Weighted Average 
Improvement (%)  Weighted Average 
Improvement (Δ)  Number of 
Patients  Number of  
Manuscripts  
36.3 
(49%)  19.9 
(30%)  39.47%  27.96  321 5 
(a total of  
6 study arms)  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 47 of 117  
 
D. Adverse Events  
The description of adverse events in the manuscripts used for the literature review is not 
uniform; some authors describe the adverse events in detail, while other do not (see the tables 
in Appendix B, listing all adverse events mentioned in the control ar ticles). In light of this 
limitation, the Company used the safety data provided in Table 7 of the FDA’s Executive 
Summary for DDD patients (n=1,350; complications=921; re -operation=814). The relevant 
section ( i.e., DDD patients) of the said table is presen ted below:  
 
It is not possible to simply sum the event rates for each adverse event to establish a control 
adverse event rate for several reasons. The table above does not specify the adverse event 
severity or device relatedness. Further, the same type of adverse even t, such as skin irritation, 
may be categorized with various degrees of severity depending on the actions taken to resolve ADEVERSE EVENT  RATE  
Screw Malposition  0.5%  
Screw Loosening  0.4%  
Rod/Plate/Screw Breakage  1.3%  
Construct Disassembly  0.1%  
Bone Fracture  - 
Graft Settling/Displacement  0.1%  
Pseudoarthrosis  5.9%  
Bleeding/Vascular Injury  0.7%  
Neurologic Injury  0.8%  
Nerve Root injury  0.3%  
Spinal Cord Injury  0.0%  
Back/Leg Pain (Radiculopathy)  0.7%  
Dural Tear/CSF Leak  1.0%  
Wound problems (Hematoma/Seroma )  0.3%  
Infection/Sepsis  3.9%  
Superficial  2.6%  
Deep  0.9%  
Skin Irritation  0.3%  
Cardiac  0.2%  
Respiratory  0.4%  
Gastrointestinal  0.3%  
Urologic/Reproductive  0.1%  
Reoperation/Revision  10.9%  
Removal of Hardware  5.5%  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 48 of 117  
 
the event. In addition, it is possible that several adverse events occurred in the same patient, 
which means summing the rates would l ead to an erro neously high adverse event rate.  
Therefore, the Company believes that a conservative estimate of relevant adverse events can 
be obtained by summing all device -related serious adverse events, all reoperations/revisions 
and all neurological inj uries.  
Therefore, the rate of failure of devices in the control group for safety reasons is 13.5% which 
includes all device -related serious adverse events  (including screw loosening , implant 
breakage and construct disassembly ), reoperations/revisions  and neurologic injuries.  
 
5.3     INCLUSION CRITERIA  
A subject will be considered eligible for inclusion in this study only if all of the following 
criteria apply:  
1. Subject  has degenerative disc disease (DDD) at  one level, from L2 to S1 vertebrae , 
with up to Grade I spondylolisthesis.   
DDD is defined as back pain and/or radicular leg pain with degeneration of the disc 
confirmed by patient history, radiographic studies, and physical examination, with 
one or more of the following factors (as measured radiographically, either by CT, 
MRI or plain film, myelography, discography, etc.): 
 osteophyte formation of facet joints or vertebral endplates;  
 decreased disc height, on average by > 2 mm;   
 scarring/thickening of ligamentum flavum, annulus fibrosis, or facet joint 
capsule;  
 herniated nucleus pu lposus;  
 facet joint degeneration/changes;  
 vacuum phenomenon.  
2. Subject is candidate for single level intervertebral fusion, with or without posterolateral 
fusion, with implantation of intervertebral body fusion device and supplemental 
fixation.  
3. Subject age  is between 21 – 72 years, and subject is skeletally mature .  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 49 of 117  
 
4. Pre-operative low back and/or leg/s pain (debilitating pain that causes  a significant 
disturbance of the routine daily physical activities) ≥ 40 mm on a 100 mm Visual 
Analogue Scale (VAS).   
5. Pre-operative Oswestry Disability Index (ODI) score ≥ 40 percentage -point, 
indicating at least moderate disability (interpreted as moderate/severe disability).  
6. Low back and/or leg/ s pain is unresponsive to prior non -surgical management for a 
minimum of six  months. Non -operative treatment includes pain medication, physical 
therapy and/or injections.  
7. Patient must understand and sign the informed consent.  
8. Patient is willing and able to meet the proposed follow -up schedule including return 
to follow -up visits and complete necessary study paperwork.  
9. Patient is willing and able to follow the postoperative management program.  
 
 
5.4       EXCLUSION CRITERIA   
A subject will not be considered eligible for inclusion in this study if any of the following 
criteria applies:  
1. Previous fusion or fusion attempts, including anterior fusion or posterolateral 
fusion, at the index level.  
2. Previous fusion or fusion attempts at the adjacent levels . 
3. Prior decompression procedures that include removal of soft and bone tissue at t he 
index  or adjacent levels . 
4. Patient is not skeletally mature.  
5. Degenerative spondylolisthesis greater than Grade I.  
6. Spinal instability at the index level with ≥ 3 mm translation and/or ≥ 5 degrees 
angulation. Determination of instability will be assessed using flexion/extension 
lateral view radiographs . 
7. Isthmic spondylolisthesis.  
 
 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 50 of 117  
 
8. Radiographically confirmed moderate or severe spinal stenosis with associated 
neurogenic claudication.  
Definitions : 
 Radiographically confirmed moderate/severe stenosis  is defined as 
reduction of ˃50% of central and/or foraminal canal diameter compared to 
the adjacent uninvolved levels.  
 Neurogenic claudication  is leg, groin, or buttock pain and/or numbness that 
worsens with walking or erect posture and is relieved with flexion of the 
spine.  
9. Systemic infection or  infection at the site of surgery.  
10. Metabolic bone disease, such as osteopenia, osteoporosis, and osteomalacia. A 
screening Questionnaire for osteoporosis, SCORE (Simple Calculated Osteoporosis 
Risk Estimation), wi ll be used to screen patients who require a DEXA bone mineral 
density measurement. If DEXA is required, exclusion will be defined as measured T -
score less than or equal to -2.5 (WHO definition).  
11. History of Paget’s disease or other bone pathologies, whether acquired or 
congenital, including  renal osteodystrophy , untreated or uncontrolled 
hyperthyroidism, hypothyroidism, or hyperparathyroidism, Ehrlers -Danlos -
syndrome, osteogenesis imperfecta, achon droplasia, tuberculosis.  
12. Personal and/or familial history NF2, and/or spinal tumor.  
13. Ankylosing spondylitis.  
14. Diffuse idiopathic skeletal hyperostosis (DISH) syndrome.  
15. Active hepatitis (viral or serum) or HIV positive, renal failure, systemic lupus 
erythema tosus, or any other significant medical conditions which would substantially 
increase the risk of surgery.  
16. Immune deficiency disease.   
17. Patient is receiving immunosuppressive or long -term steroid therapy.  
18. Active malignancy or other significant medical como rbidities.  
19. All concomitant diseases that can jeopardize the functioning and success of the 
patient.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 51 of 117  
 
20. Allergy to any component of the investigational device, including carbon fiber -
reinforced polyetheretherketone (CFR -PEEK), titanium, and tantalum . 
21. Pregnanc y, or female subject interested in become pregnant during the duration of the 
study.  
22. Current chemical dependency  (e.g., drug and/or alcohol abuse, according to DSM -V 
definition), as well as those with a history of such abuse . 
23. Uncontrolled de pression, psychosis, or other symptoms of a mental disorder that, in 
the investigator’s opinion, likely would make the subject unable to comply with the 
study procedures and could affect the study outcome.  
24. Treatment with drugs that may interfere with bone metabolism , such as  
glucocorticosteroids, calcitonin, bisphosphonates, bone therapeutic doses of 
fluoride, bone therapeutic doses of vitamin D or vitamin D metabolites, and 
treatment by chemotherapy.  
25. Morbid obesity (BMI ≥ 40). 
26. Current smokers (including 3 months pr ior to surgery).  
27. Scoliosis, Cobb angle greater than 11°.  
28. Vertebral fractures.  
29. Severe muscular, neural or vascular diseases that endanger the spinal column.  
30. Missing bone structures, due to severely deformed anatomy or congenital anomalies, 
which  make good  anchorage  of the implant impossible.  
31. Paralysis.  
32. Current use of other investigational drug or device.  
33. The patient is involved in a worker’s compensation case or spine -related litigation.  
34. The patient is a prisoner.  
Note : The time elapses between the diagnostic studies required for entry and enrolment into 
the study is limited to up to three  months.  
 
5.5     NUMBER OF PATIENTS A ND PATIENT SELECTION  
Patients Number:  
A total of 55 patients will be recruited for the study  (up to 15 subjects will  be recruited in this 
site). Their results will be combined with an additional 45 patients from  the ongoing OUS 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 52 of 117  
 
study, the details of which are presented in the Investigator Brochure . When combined with 
the patients from the ongoing OUS study , 55 patients was deemed sufficient for this 
confirmatory, single -arm study . Therefore, the total effective sample size is about 100 
patients.  
Patients Selection:   
In order to be included in this study, patients will have to fulfill all the Inclusion  Criteria and 
none of the Exclusion Criteria, as well as to sign and date the Informed Consent Form.  
All patients' full medical history will be recorded and all patients will undergo a complete 
general physical and neurological examination. Plain A -P and l ateral X -Ray films, as well as 
lateral flexion -extension X -Rays, will be performed prior to surgery .  
Neurological examination will be performed  to confirm that the patient' clinical signs and 
symptoms are consistent with the baseline disease level/s demon strated per imaging.  
An anesthesiologist will assess the patient for general anesthesia, according to the routine 
practice.  
 
5.6      STUDY SITES  
Up to eight  sites may participate in the study. At least two sites will be in the USA, recruiting 
at least 30 patients.  
 
5.7      STUDY DURATION  
The study is expected to last up to 36 months (total duration), including patient enrollment  
and a post -operative follow -up period of 24 months per subject.  
 
The primary safety and effectiveness analyses will be performed at 24 months. The collected 
information will be submitted to the FDA as part of a 510(k) Premarket Notification after all 
patients have completed 24 months of follow -up. In case of satisfactory results, the Company 
intends to submit the results o f the study to the FDA, after all patients have completed the 12 
months follow -up, as part of a Premarket Notification (510(k)). It is emphasized, that all 
patients will be additionally followed at 24 -month time point, and afterwards annually, until 
the la st patient completed 2 -year follow -up. It is noted, that at the time all subjects from IDE 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 53 of 117  
 
study reach 12 -month follow -up, it is expected that 2 -year supportive data from the original, 
ongoing OUS clinical study  with the investigational device will be avai lable.  
Patients will be followed and assessed both clinically and radiographically after surgery at 
follow -up visits.  
Evaluation time points shall be conducted at the following intervals:  
 Preoperatively ( with up to 3 mo nths between the diagnostic studies to enrolment ); 
 Operatively;  
 Postoperatively, at discharge from hospital;  
 Postoperatively, at 6 weeks ± 2 weeks from surgery;  
 Postoperatively, at 3 months ± 2 weeks from surgery;  
 Postoperatively, at 6 months ± 1 month from surgery;  
 Postoperatively, at 12 months ± 2 months from surgery.  
 Postoperatively, at 24 months ± 2 months from surgery.  
Afterwards, subjects will be clinically evaluated annually, until the last patient  has completed 
2-year follow -up. 
 
At baseline, discharge, and at  follow -up sessions, radiographic evaluation, pain  and 
functionality evaluations , and subject's  overall well -being assessment  shall be performed. 
Assessment of subject' satisfaction shall be performed postoperatively, starting at 6 -week 
follow -up.    
Compl ications/adverse events shall be evaluated operatively and at each evaluation time 
points, as well as throughout the study.    
 
Refer to Section s 5.9 and 5.10 for a detailed schedule and assessment description, 
respectively.  
 
5.8       MISSING DATA  
Incomplete information may be available for a  subject for various reasons:  
 Subject stopped participation in the study at its own request;  
 Continuing the follow -up is not possible/ subject lost to follow -up; 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 54 of 117  
 
 Subject stopped participation in the study at the Investigator’s discretion.  
 
In general, in cases where information will be available for a certain missing data point from a 
previous and from the next follow -up, an interpolation of the values shall be performed. 
Missing data from patients that were lost to follow -up will be handle by "last value carried 
forward"  approach ( i.e., the last value obtained from a subject will be used for the analysis ).  
 
5.9         PROCEDURES  
5.9.1        PREOPERATIVE MANAGEMENT  
a. The Investigator will select the subjects according to the inclusion and exclusion 
criteria, as described in Sections 5.3 and 5.4, respectively .  
b. The Investigator will be acquainted with the technique and instrumentation required 
for the procedure. Trainin g will be provided by the Sponsor or its authorized 
representatives in accordance with the Training Protocol ( Appendix  C). 
c. The Investigator will be familiar with the Protocol of the clinical trial.  
d. Signed written Informed Consent must be obtained for all s ubjects.  
e. The patients shall be instructed to refrain from the use of NSAIDS for two weeks 
prior to surgery.  
f. All female subjects who are of child bearing age should present a negative beta -
HCG blood (pregnancy) test or submit a signed statement that she is using at least 
one conventional contraceptive method and that to the best of her knowledge she is 
not pregnant. Such woman shall be informed of the risks involved in participating in 
the study while pregnant and cautioned to inform the study personnel if s he becomes 
pregnant during the timeframe of the study.  
 
Pre-procedure assessment will be conducted according to the outline provided in the Case 
Report Forms (CRFs) booklet.  
Pre-procedure examination includes (refer also to Table 8 below):  
 Demographic data 
 Full medical history, including concomitant medications  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 55 of 117  
 
 Physical examination  
 Neurological examination  
 X-Ray evaluation  
The results of the said examinations shall be recorded.  
During the pre -operative session, the following forms shall be completed (refer also to Table 
9 below) : 
 Pre-operative CRF  
 Patient baseline questionnaires ( Visual Analogue Scale (VAS, for back and leg 
pain assessment), Oswestry Disability Index (ODI), and 12-Item Short Form Health 
Survey  (SF-12) 
 
5.9.2       SURGICAL PROCEDURE  
The surgical procedure is described in the system Surgical Technique  (Appendix A ).  
The Operative CRF shall be completed.  
In case of an adverse event, the appropriate CRF should be filled.  
 
5.9.3        POSTOPERATIVE MANAGEMENT  
In general, postoperative management shall be conducted according to the description in the 
CRFs.  
 
Immediate post -operative management  should be as per routine hospital standard of care.  
 
Prior to discharge , the following examinations/tests shall be perf ormed (refer also to Table 8 
below and to the description in the Discharge C RF):  
 Physical examination    
 Neurological Examination   
 X-Ray evaluation  
The results of the said examinations shall be recorded on the Discharge C RF. 
In addition, the patient shall be interviewed regarding adverse events; in case of an adverse 
event, the appropriate form should be filled.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 56 of 117  
 
 
The patients shall be instructed to refrain from the use of NSAIDS for three months post -
operatively.  
 
During follow -up visits , the following post -operative examinations/tests shall be performed 
(refer also to Table 8 below and to the description in the post -operative C RFs):  
 Physical examination   
 Neurological Examination    
 X-Ray evaluation  
The results of the said examinations shall be recorded.  
At every follow -up visits the following forms shall be completed ( refer to Table 9): 
 Post-operative CRF  
 Patient follow -up questionnaires (VAS (pain), ODI, SF -12, VAS (donor site pain, if 
appli cable), and VAS (satisfaction))   
In addition, the patient shall be  interviewed at each follow -up visit regarding adverse events, 
and the appropriate form should be filled. If a non -scheduled postoperative visit results from 
such an event, it should be noted on the form.  
 
Table 8 below lists the assessment schedule and e xaminations . 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 57 of 117  
 
Table 8: Assessment  Schedule  
Description  Pre-
Procedure  Operation  Discharge  6 Weeks 
Visit  3 Months 
Visit  6 Months  
Visit   12 Months 
Visit  24 Months  
Visit  Annual  
Visit § Unscheduled  
Visit  
Inclusion/Exclusion Criteria  √          
Informed Consent  
(signed & dated)  √          
Demographic & Medical 
History  √          
Physical Examination  √  √ √ √ √ √ √ √ √ 
Neurological Examination  √  √ √ √ √ √ √ √ √ 
X-Rays (AP, Lateral and 
Flexion/Extension)  √                                                                                                                                                                                                        Fluoroscopy  √ * √ * √ * √ √  √  √  √ ** 
Patient Questionnaires  
(VAS (Pain), ODI, SF -12, 
VAS (Satisfaction))  √ ¤   √ √ √ √ √  √   
CT Scan       √ ¥ √ ¥ √ ¥ √ ¥  
AE Recording   √ √ √ √ √ √ √ √ √ 
§     Will be performed after the 24 -month follow -up, until the last patient complete s 2-year follow -up. 
*    Except for flexion/extension X -rays.  
**  Will be performed only if required according to the physician discretion.  
¤    Except for patient satisfaction VAS.  
¥    CT scan will be conducted for patients in whom bridging bone status  cannot be determined in X -Rays . 
Table 9 below lists the Questionnaires and Forms that need to be completed during baseline and  postoperatively evaluations.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 58 of 117  
 
 
Table 9: Forms/Questionnaires to be Completed at Pre -Op. and Follow -Up Visits  
Form Type  Pre- 
Operation  Operation  Discharge  6 weeks  
Post-Op. 3 Months  
Post-Op. 6 Months  
Post-Op. 12 Months  
Post-Op. 24 Months  
Post-Op.  Annual  
Visit *  Unscheduled 
Visit  
Pre-Op. CRF 
(Enrollment and 
Baseline Forms)            
Operative CRF            
Discharge CRF            
Post-Op. CRF            
Unscheduled Visit 
CRF            
Medications CRF – 
Follow Up    Medications Form should be completed at discharge and follow -up sessions,  
in case any concomitant medication was used during hospitalization  or since last visit, respectively  
Adverse Event CRFs 
(AEs, SAE, 
Additional Surgery)   
When applicable  
Protocol Deviation   When applicable  
Conclusion CRF    At 24  Months, or when applicable  
VAS (Pain),  
ODI & SF -12           
VAS (Donor Site 
Pain), if applicable            
VAS (Satisfaction)            
*    Will be performed annually after reaching the 24 -month follow -up, until the last patient complete s 2-year follow -up         
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 59 of 117  
 
Subjects who shall withdraw from the study will have the Conclusion CRF completed 
for them upon their request to withdraw from the study. The reason for withdrawal 
and any alternative treatment sugges ted to the patient shall be indicated on the form. 
In case a subject who is lost to follow up returns at a later stage, this will be indicated 
as a remark on the Conclusion CRF along with the reason the patient missed the 
previous follow -up session(s).  
 
5.10       EVALUATION OF PRIMARY  OUTCOME  MEASURES   
5.10.1      FUSION  EVALUATION  
Fusion will be evaluated radiographically, by A -P, lateral and flexion/extension X -
Rays ( flexion/extension films will be used for the assessment of angular and 
translational motions ). As detailed below, in case of inconclusive findings regarding 
bridging bone, a CT scan will also be performed, and evaluated by the core lab.   
 
Fusion assessment shall be made postoperatively, starting at 6 months and at each 
follow -up session af terwards.    
 
Each fusion area (between the endplates, at right  posterolateral, and at left 
posterolateral, as applicable) will be assessed separately.  
 
All radiographs will be read by two independent, board -certified, radiologists from  
Medical Metrics, In c., with  experience in musculoskeletal imaging, blinded to clinical 
outcomes, and without any financial interest in CarboFix Orthopedics, to ensure 
consistent reading of the radiographs and elimination of bias . In the case of a 
disagreement between the two  radiographic assessors, a third independent reviewer  
will evaluate the radiographic images to adjudicate the findings.  
 
Please refer to Appendix D for radiographic protocols, including Image Acquisition 
Protocol, Image Transfer Protocol, and Radiographic Evaluation Protocol. All said 
protocols were provided to CarboFix by Medical Metrics, Inc.   
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 60 of 117  
 
Fusion Radiographic Patient Success  is defined  when all t he following radiographic 
endpoints are met at 24 months:  
a. Angular motion ˂ 3º; AND   
b. Translational motion ˂ 3 mm; AND  
c. Presence of continuous bridging bone between the involved motion segment, 
i.e.: 
 Presence of interbody (between endplates) bridging bone and  absence of 
radiolucency > 50%; OR 
 Presence of left posterolateral bridging bone; OR 
 Presence of left posterolateral bridging bone.  
 
Regarding angular motion, reporting of subjects will be provided in the following 
three groups:  
1.  those with ≤ 3º total  angular motion,  
2.  those between 3º and 5º of motion, and  
3.  those with ≥ 5º of motion.  
 
In case bone graft would be placed in the interbody space as well as posterolaterally, 
on both sides, bridging would be assessed in each of the three areas. Bridging in any 
one area would be considered adequate to document the presence of affirmative 
bridging.  
 
Radiolucency will be evaluated as the percent coverage of radiolucent lines along the 
graft / endplate interface. There will be a single assessment for the superior and 
inferior bone / graft interfaces combined. Radiolucency will be evaluated primarily 
from lateral views. The view (neutral, flexion or extension) showing the most severe 
extent of radiolucency will be used to document the assessment.  
Radiolucency will be used to document bone resorption. Particularly in the early 
stages of healing, poor conf ormance of the graft with the endplate geometry, i.e. poor 
“fit and fill”, will not be identified as radiolucency.   
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 61 of 117  
 
Radiolucency  will be graded in accordance with the following definitions:  
None : No radiolucent lines along the interbody graft / endplate  interface.  
Mild :  ≤ 25% radiolucent lines along the interbody graft / endplate interface.  
Moderate : 26% - 50% radiolucent lines along  the interbody graft / endplate 
interface.  
Severe : > 50% radiolucent lines along the interbody  graft / endplate interface.  
 
Non-fusion  will be indicated in the following cases:  
Angular motion ≥ 3° OR translational motion ≥ 3 mm OR absence of continuous 
bridging bone, i.e.: 
 Absence of interbody bridging bone and presence of radiolucency >50%; 
AND  
 Absence of left posterolateral bridging bone; AND  
 Absence of right posterolateral bridging bone.  
 
Possibly fusion : Patients  in whom the status of bridging bone is inconclusive will 
undergo fine cut CT scan to determine bridging bone and fusion status. At each 
timepoint, s tarting at 6 months, any inconclusive X -Rays assessment relates to 
bridging bone shall be repeated within window, using CT.  
 
Information regarding the CT scans  (including the procedures for obtaining and 
transmitting the CT scans) is presented in the Radi ographic Protocol ( Appendix D).  
Definition of bridging bone evaluated in CT scan is as follows (on top of motion 
evaluated by flexion/extension X -Rays):  
Presence of continuous bridging bone between the endplates; or between the right 
facets, pedicle and/ or transverse processes; or between the left facets, pedicle and/or 
transverse processes, as applicable .  
 
The fusion rate obtained in the study shall be compared to the fusion rates reported in 
the literature (as summarized in Section 5.2.1). 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 62 of 117  
 
5.10.2     PAIN AND  FUNCTION EVALUATION  
Pain and functionality will be assessed using dedicated questionnaires.  
VAS (Back , Right Leg, and Left Leg  Pain) : The assessment of pre - and post -
operative pain shall be  performed using scores determined from measurements of 
responses  to pain question for each location ( i.e., low back, right leg, and left leg), 
provided on a 100 mm Visual Analog Scale (VAS). The anchor points are “No Pain” 
(0 mm) and “Severe Pain” (100 mm). Patients will be instructed to draw a single line 
across the s cale at the point that best described  their level of pain.  
The pain VAS assessment will be administered preoperatively as well as at each 
postoperative visit, starting at 6 weeks.  
  
ODI (Functionality) : The Oswestry Disability Index (ODI) will be used to assess 
function. The ODI questionnaire is based on patient’s responses to ten questions, 
which focus on pain intensity, personal care, lifting, walking, sitting, standing, 
sleeping, sex life, social life, and traveling. Each question has six possible answe rs. 
The responses to each question ranges from zero to five points. A lower numeric 
score represents a better pain and disability status regarding that variable (0 points for 
functionality with no associated pain or no extra pain; 5 points for inability to  perform 
function due to pain). A total ODI score is determined by adding the scores of the 
individual questions and dividing that total by the maximum possible total score (50 if 
all questions are answered); this yields a percentage. Therefore, ODI scores  shall be 
presented ranging from 0% to 100%, with a lower percentage indicating less pain and 
disability.  
The ODI questionnaire will be administered preoperatively as well as at each 
postoperative visit, starting at 6 weeks visit.  
 
Clinically Meaningful Improvements  –  
 Individual patient clinically meaningful improvement with respect to pain is 
defined as postoperative improvement at 24 months of at least 20 mm on a 100 
mm VAS from the baseline level. Data regarding pain improvement will be 
provided for all pain components ( i.e., low back, right leg and left leg). The 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 63 of 117  
 
above improvement criterion of 20/100 mm refers to the dominant pain 
component for each patient. For example: if the preoperative VAS (pain) for a 
given patient was 90 (low back), 60 (right leg), and 40 (left leg), improvement 
of at least 20 mm will be required for the back pain component. Improvement 
in both legs, though, will be also reported.  
 Individual patient clinically meaningful improvement with respect to 
functionality  is defined as p ostoperative improvement at 24 months  of at least 
15 points on the ODI graded on a 100 -point scale as compared to baseline 
assessment.  
 
It is noted, that the indicated improvement values in pain and function are regarded 
clinically meaningful and were use d in other, IDE studies for similar devices.  
 
Average improvement and standard deviation for VAS (pain) and ODI, as well as the 
proportion of patients that met the success criterion for VAS and ODI, will be 
reported.  The VAS and ODI results obtained in th e study shall be also compared to 
VAS and ODI results reported in the literature (as summarized in Section 5.2.1).   
 
5.10.3  SAFETY  EVALUATION  
The safety evaluation will be based on the reported complications and adverse events 
(AEs), including su bsequent surgical interventions  and neurological status. 
Complications/A es shall be evaluated at each follow -up session, as well as throughout 
the study.  
  
1. Complications/Adverse Events  
All the reported complications/adverse events, whether device -related or not, 
including "anticipated" complications, will be recorded.  
Refer to Section 5.14.4.1  for adverse event definitions.    
 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 64 of 117  
 
2. Subsequent Surgical Intervention  
Information regarding subsequent interventions will include category of procedure, as 
defined below, the reason for the procedure and whether or not the subsequent 
procedure constitutes a study failure.  
Subsequent  surgical intervention will be categorized  as a revision, removal, re -
operation, or supplemental fixation at the affected level/s, as defined hereinafter.  
Revision  – a second procedure that adjusts or in any way modifies or removes part of 
the original implant configuration, with or without repla cement of a component. A 
revision may also include adjusting the position of the original configuration.  
Removal  – a procedure where all of the original system configuration are removed 
with or without replacement.  
Reoperation  – any surgical procedure at t he involved level/s that is not removal, 
modification, or addition of any components to the system ( e.g., irrigation and 
debridement).  
Supplemental Fixation  – a procedure in which additional instrumentation not under 
study in the Protocol is implanted.  
Subsequent interventions in spinal studies include epidural injections, the 
implantation of spinal stimulators, and rhizotomies.  
 
3. Neurological Status  
A neurological examination will be performed preoperatively and at discharge, and at 
all postoperatively visits, to assess neurological status. The evaluation of neurological 
status will include motor, sensory, reflex, straight leg raising, and tenderness 
assessments, as hereby described. Each component shall be assessed separately on 
each anatomical side (le ft, right). The following paragraphs describe the five 
neurological examinations.  
The motor evaluation  measures the muscle strength in major muscle groups ( Gluteus 
Maximus  (hip extension); Iliopsoa  (hip flexion ); Quadriceps (knee extension); 
Hamstrings ( knee flexion ); Anterior Tibial Group ( ankle dorsiflexion ); Extensor 
Hallucis Longus (great  toe extension ); Posterior Tibial ( ankle plantar 
flexion /eversion); and Flexor Halluces (great toe flection )). Muscle strength  is 
evaluated on a 6 -point scale ranging from 0 to 5  according to the following key 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 65 of 117  
 
describing the ability of the patient to move the lower extremities against resistance 
provided by the examiner:  
 0 – no movement;  
 1- muscle contraction;  
 2 – lateral movement;  
 3 – against gravity;  
 4 – against moderate resistance;  
 5 – against full resistance.  
 
Light -touch will test sensation  for all lumbar and sacral dermatomes in comparison to 
the contralateral site. The sensation shall be graded as equivalent (normal), impaired, 
absent, as compared to the contralateral side . 
 
Reflexes  (Patella and Achilles) are evaluated according to Bate’s Reflex Scale (a 5 -
point scale ranging from 0 to 4) as follows:  
 0 – no reflex;  
 1 – somewhat diminished, low normal;  
 2 – average, normal reflex;  
 3 – brisker tha n average;  
 4 – very brisk, hyperactive.  
 
Straight leg raising  is assessed by measurement of the degree of movement required 
to reproduce symptoms. A positive test is considered when the patient reports 
worsening of pain between 30 and 70 degrees of hip p assive flexion while knee is 
extended.  
 
Tenderness  will be evaluated by palpation of the lower spine area – lumbar 
paraspinal region, lumber spinous process, sacroiliac joint, and sciatic notch. 
Tenderness shall be graded as negative or positive ( i.e., pal pation provokes painful 
sensation).  
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 66 of 117  
 
Patient Success  –  
Individual patient success with respect to safety  is defined as:  
 No worsening in neurological status (motor, sensory, reflex, straight leg 
raising, and tenderness assessments) and no new permanent neurological  
deficits present for at least 2 successive visits at or beyond 6 months (out to 
24 months) ; 
 Absence of device -related  serious adverse events through 24 months ; 
 Absence of subsequent surgical interventions at the index level through  24 
months.  
 
5.11 EVALUATION  OF SECONDARY  OUTCOME  MEASURES  
A. Patient's Overall Well -Being and Satisfaction  
Subject's overall well -being and satisfaction will be assessed using dedicated 
questionnaires . 
 
SF-12 (Subject Overall Well -Being) : 
Subject's overall well -being (qualit y of life) will be assessed using the 12 -Item Short 
Form Health Survey (SF -12), which is a multipurpose short -form quality of life 
instrument with 12 questions selected from the SF -36 Health Survey. SF-12 
questionnaire is designed to measure general health  status from the patient's point of 
view. Results are expressed in terms of two meta -scores: the Physical Component 
Summary (PCS) and the Mental Component Summary (MCS). The PCS Score is a 
composite of the Physical Functioning, Role Functioning, Bodily Pai n and General 
Health Scales within the SF -12 instrument. The MCS  is a composite of the Vitality, 
Social Functioning, Role -Emotional and Mental Health Scales within the SF -12 
instrument.  The SF -12 is a normative based instrument. PCS and MCS are computed 
using the rating on 12 questions from 0 to 100, where a 0 score indicates the lowest 
level of health and 100 indicates the highest level.   
The SF -12 questionnaire will be administered preoperatively as well as at each 
postoperative visit, starting at 6 weeks  visit.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 67 of 117  
 
VAS (Patient Satisfaction) :  
Patient satisfaction will be assessed using a 100 mm VAS, completed by the patient. 
Satisfaction scores shall be obtained from patient responses, and shall be expressed in 
millimeters (mm). The anchor points are “Completely Not Satisfied” (0 mm) and 
“Completely Satisfied” (100 mm).  Patients shall be instructed to draw a single line  
across the scale at the point that best described their level of satisfaction.  
VAS questionnaire for satisfaction will be administere d at each postoperative visit, 
starting at 6 weeks  visit.  
 
B. Donor Site Pain  
The assessment of pain at the donor site (iliac crest) shall be performed using scores 
determined from measurements of responses to pain question, provided on a 100 mm 
VAS. The anc hor points are “No Pain” (0 mm) and “Severe Pain” (100 mm). Patients 
for which bone graft was harvested from their iliac bone will be instructed to draw a 
single line across the scale at the point that best described their level of pain at the 
donor site.  
VAS questionnaire for donor site pain will be administered at each postoperative visit, 
starting at 6 weeks  visit.  
 
C. Operative Information  
Parameters related to the surgery, such as blood loss and operation time will be also 
evaluated for all patients participating in the study.  
The volume of blood loss  during operation will be recorded for each patient, and 
average blood loss and standard d eviation will be reported in cubic centimeter  (cc). 
Operation time  (skin -to-skin) will be recorded for each patient, and average operation 
time and standard deviation will be reported in minutes.  
  
5.12        STUDY  SUCCESS  CRITERIA   
The results of the study at 12 months and 24 months postoperatively for all 
participating subjects will be evaluated, with reference to the reported results from the 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 68 of 117  
 
literature, as summarized in Section 5.2.1. In addition, assessment of success rate will 
be conducted at each time point, as applicable.  
In addition to evaluating individual patient success as the primary composite 
endpoint, each element of the composite will be evaluated individually  as secondary 
endpoints, as described below . 
Fusion  – Success  for the fusion outcome measure will be defined as two year  fusion  
rate comparable to the two and one year fusion rates presented in the literature. The 
pooled results of the Company literature research  (for patients with DDD treated with 
pedicle screws with PLIF/ALIF/TLIF  and/or PLF) , as presented in Section 5.2.1, 
demonstrated at 12 and 24 months postoperatively fusion rates in the different studies 
ranging from 77% to 97%.    
As discussed in Section 5.2.1.A , the weighted  average for the fusion rate of the ten 
articles is 87.79%.  Based on the literature, we believe our fusion rate will be 88%.    
The assumed fusion rate of 88%  has a 95% confidence interval of ±6.4% for  100 
patients . Notably, t he lower bound of this confidence interval , 81.6 %, is within t he 
range of the fusion rates reported in the selected literature . 
 
Safety  – Success with regard to safety outcome measure is defined as no worsening in 
neurological status (motor, sensory, reflex, straight leg raising, and tenderness 
assessments) and no new permanent neurological deficits (present for at least 2 
successive visits at or beyond 6 months), absence of device -related  serious adverse 
events, and absence subsequent surgical interventions at the index level, through 24 
months, comparable to neurological deficit, device -related  serious adverse events, and 
subsequent surgical interventions rates presented in the literature .  
Based on the literature review in FDA’s Executive Summary, the rate of these events 
in the literature control is 13.5%.   
Therefore, the Company estimates that the adverse event rate for these events will be 
13.5%. With a sample size of 100 patients, thi s adverse event rate has a 95% 
confidence interval of ±6.7%.   
As indicated above, it is believed that at the time all subjects from the IDE study 
complete one year follow -up, supporting safety data for 24 months  will be available 
for about 45 patients fro m the ongoing, OUS study.   
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 69 of 117  
 
Pain  - Individual patient , clinically meaningful , improvement with respect to pain is 
defined as postoperative improvement at 24  months of at least 20 mm on a 100 mm 
VAS  from the baseline level.  
Value of 73% of patients with ≥20  mm improvement. This value is selected as it is 
consistent with the performance of the Silhouette Spinal Fixation System reported in 
P070031.  
 
Function  - Individual patient , clinically meaningful , improvement with respect to 
function is defined as postope rative improvement at 24 months of at least 15 points on 
the ODI graded on a 100 -point scale as compared to baseline assessment.  
Value of 55% of patients with ≥15 points improvement. This value is selected as it is 
consistent with the performance of the c ontrol group reported in P050010.  
 
Individual Patient Success (Overall Success)  
Individual patient success ( i.e., overall success) will be determined at 24 months and 
is defined as a composite primary endpoint. An individual subject will considered a 
success if all of the following criteria are met:  
 Presence of continuous bridging bone betw een the involved motion segment  at 
24 months, i.e.: 
 Presence of interbody bridging bone and absence of radiolucency > 
50%; OR 
 Presence of left posterolateral bridging bone; OR 
 Presence of left posterolateral bridging bone.  
 No motion on flexion/extension films  at 24 months  (success is defined as 
angular motion ˂ 3º  and translational moti on ˂ 3 mm ); 
 Improvement of at  least 20 mm on a 100 mm VAS from baseline level at 24 
months;  
 Improv ement of at least 15 points on the ODI graded on a 100 point scale at 
24 months as compared to baseline ; 
 No worsening in neurological status (motor, sensory,  reflex, straight leg 
raising, and tenderness assessments) and no new permanent neurological 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 70 of 117  
 
deficits present for at least 2 successive visits at or beyond 6 months (out to 24 
months);  
 Absence of device -related  serious adverse  events through 24 months;  
 Absence of subsequent surgical interventions  at the index level through 24 
months.  
The study will be considered a success if the overall success rate for the CarboClear 
Device is 41%. This value is selected as it is consistent with the performance of the 
control group s reported in P050010 and P070031.  
 
5.13      STATISTICAL  ANALYSIS  
5.13.1    SAMPLE SIZE JUSTIFICATION  
Fifty five (55) patients will participate in the IDE study.  However, the statistical 
analysis will be conducted for a total sample size of 100 patients  as the Company is 
adding data from ongoing OUS sites to data collected according to this IDE. FDA 
confirmed that the proposed IDE sample size, in addition to the ongoing OUS data, 
would be sufficient. It is emphasized, that prospectively enrolled patients at O US sites 
will participate in the study presented in this IDE ( i.e., will be part of the 55 patients 
of the IDE study), and will follow the same protocol that representing homogenous 
cohort of DDD patients with up to Grade I spondylolisthesis and no  greater than mild 
stenosis . Only currently enrolled patients in the ongoing OUS sites that are adequately 
per IDE protocol (about 45 patients)  will be considered in the statistical analysis. 
Adequacy for OUS study patients being included in the statistica l analysis will be 
based, mainly, on patient meeting the eligibility criteria (inclusion/exclusion) for the 
IDE study, i.e., DDD patients, with up to Grade I spondylolisthesis and/or with up to 
mild stenosis (the ongoing OUS study was approved for more het erogenic 
population). Other parameters, as detailed below, are very similar when comparing 
the ongoing OUS study and the study suggested in this IDE: The same system and 
surgical technique are used in both studies. The IDE study includes the use of an 
interbody fusion device while the OUS study does not. Thus, the data from the OUS 
study may be regarded as worst case in terms of fusion rates as  only posterolateral 
fusion was made and interbody fusion device  was not used . Patient population is 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 71 of 117  
 
considered sim ilar in both studies (demographically, as well as indications wise, as 
non-DDD patients will not be included in the statistics for the IDE study). The 
endpoints for the IDE study are also evaluated in the ongoing OUS study, using the 
same assessment tools : fusion (radiographs), safety, pain (VAS), function (ODI), and 
patient well -being (SF -12). Follow -up time points are similar in the ongoing OUS 
study (4 weeks, 3 months, 6 months, 12 months and 24 months) and the suggested 
IDE study (6 weeks, 3 months, 6 m onths, 12 months, and 24 months, and then 
annually, until the last patient completed 2 -year follow -up).   
As it is estimated that data for about 45  patients will be available from the ongoing 
OUS study , the total sample size is effectively 100 patients.  
 
It is noted, that the suggested investigation is a confirmatory study, aimed at 
supporting the safety and effectiveness of the CarboClear System. As indicated 
before, comprehensive pre -clinical testing was conducted for the system, with good 
results, subst antially equivalent to the results of cleared predicate devices (metal, 
rigid, pedicle screw systems). In addition, interim results from the ongoing, OUS 
study with the CarboClear System support the safety and effectiveness of the system 
for DDD patients ( as summarized in the Investigator Brochure , the OUS trial enrolls 
DDD patients, as well non -DDD patients/patient with  DDD and other pathologies. 
The latter may be regarded as worst case with respect to pedicle screw 
instrumentation and fusion in comparison  to DDD patients).  
Based on the above, and taking into account the selection of narrow indication for the 
study that results in homogenous population, the number of 55 subjects for this 
confirmatory study is thought to be sufficient (with statistical analy sis of 100 
patients).    
 
5.13.2  POOLABILITY OF DATA 
All data obtained from up to 8 sites participating  in this study will be pooled into a 
single database for which data analysis will be performed.  
Poolability is considered to be appropriate as all sites will use the same study Protocol 
and Appendi ces (such as Case Report Forms). Also, all investigational teams will 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 72 of 117  
 
receive the same training by the Sponsor representative. The appropriateness of 
pooling data from multiple centers is necessarily enhanced by train ing all 
participating centers to follow the same protocol, with, among other things, clearly 
defined inclusion and exclusion criteria for study participation. Periodic monitoring 
visits shall be conducted to verify full understanding and fulfillment of the  procedure 
at all sites. In addition, performance and evaluation of X -Rays images will be 
performed using the same means and definitions, according to written radiographic 
protocol, by the same independent reviewers. Likewise, independent reviewer s 
(clinic al event s committee)  will assess all adverse events to determine the severity of 
the events and their relationship to the procedure and investigational device (please 
refer to Section 5.14.4). Thus, this multi -center study includes standardization of 
subje ct enrollment, data collection and evaluation, and adverse event reporting  and 
evaluation , with all sites following the requirements of the same Protocol.  
Prior to pooling the data, the demographic information items will be reviewed to 
verify that their a verage values for all sites are within one standard deviation.  
Furthermore, the Company will perform poolability analyses of baseline 
characteristics and cage type in order to confirm the homogeneity of the entire patient 
population.  
In particular, before  combining the US and OUS data ( e.g., patients from US and 
patients from OUS in the proposed study ; as well as patients from the proposed IDE 
study and pati ents from the ongoing OUS study ) the baseline demographics and 
prognostic characteristics between th e groups will be compared to evaluate the 
poolability of the US and OUS data.  The characteristics to be compared include:  
•   Age 
•   Gender  
•   Pre-operative VAS  
•   Pre-operative ODI  
•   Diagnosis (DDD, Degenerative Spondylolisthesis ≤ Grade I, Spinal St enosis < 
40%, or other)  
•   Previous spinal surgical treatment (yes/no)  
•   Type of interbody fusion device used (for subjects participating in the IDE 
study)  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 73 of 117  
 
These characteristics will be compared using a t -test or a Wilcoxon rank sum test for 
continuous variables and a Chi -square test or a Fisher’s exact test for categorical 
variables, as appropriate.  If the OUS data is similar to the US data then the data will 
be pooled and analyzed as a single group.  If the US and OUS data are dissimilar, then 
the combi ning of the two datasets may need to be reevaluated.  The reasons for 
dissimilarity will be investigated and the effect of investigational treatment in the 
presence of the disparate results will be discussed.  In addition, primary analysis 
results stratified  by US and OUS sites will be presented.     
 
With regards to the ongoing OUS study – as described in the above Section 5.13.1, 
poolability of data for the statistical analysis is deemed eligible.  
  
5.13.3  ANALYSIS POPULATIONS  
Intent -to-Treat (“ITT”): All patients  treated with the device.  
Per-Protocol (“PP”): All patients who did not have a major protocol violation and 
who completed all study visits.  
The primary analysis will be based upon the ITT population. Additional analyses 
using the PP population will also be  presented in the final report.  
 
5.13.4  STATISTICAL ANALYSIS OF DATA 
In general, the statistics for numerical variables shall be presented as mean ± standard 
deviation, median, minimum and maximum values (range), and sample size 
(continuous data). Categorical dat a will be presented as counts (numbers) and 
percentage of the total (rate ). In addition, 95% confidence intervals will be presented 
for the fusion and adverse events rates. Furthermore, subgroup summary statistics will 
be calculated where necessary.  
Where  adequate, comparison between subgroups ( e.g., with/without mild stenosis ; 
with/without prior discectomy ) shall be presented with differences ( e.g., P-values). It 
should be noted that comparisons between subgroups  are supportive analyses; these p -
values wi ll not be adjusted for multiplicity.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 74 of 117  
 
Adverse events (AE)  data will be listed individually and summarized. Overall AE 
results will be presented both on a per -subject basis and per -event basis ( i.e., total 
number of subjects with each event and total number  of events reported).   
Results of AE seriousness and device -relatedness will be presented as well.  
The report of AEs based on specific type of event will be according to the following 
AE terms, listed in the table below, and in accordance with FDA list o f risks 
applicable for pedicle screw spinal systems ( FDA’s Executive Summary, Table 11 ). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, as per the FDA recommendation, the adverse events will be further 
analyzed according to the Adverse Events table provided in  Section 5.14.4.2 . 
 
Patients who withdraw from the study (following implantation of the investigational 
device), are lost to follow -up, or for whom data is missing, will be analyzed 
individually based on the information already available for the patient. In general, if 
sufficient data will be available for the patient based on previously gathered ADEVERSE EVENTS  
Implant Malposition  
Implant Loosening  
Device Breakage  
Construct Disassembly  
Bone Fracture  
Graft Settling/Displacement  
Loss of Correction  
Pseudoarthrosis  
Bleeding/Vascular Injury  
Neurologic Injury  
Back/Leg Pain (Radiculopathy)  
Dural Tear/CSF Leak  
Wound problems   
Infection/Sepsis  
Skin Irritation  
Cardiac  
Respiratory  
Gastrointestinal  
Reoperation/Revision  
Death  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 75 of 117  
 
information  (e.g., at previous follow -up sessions) or if, in cases where fusion occurs 
prior to withdrawal and no adverse events have been observed, the patient may be 
regarded as a success.   
 
5.14 SUMMARY OF RISK ANALYSIS  
5.14.1  POSSIBLE HAZARDS  
The risks and possible adverse events associated with the use of CarboClear Pedicle 
Screw System and the discussed procedure are expected to be similar to - and are not 
expected to be at a higher rate than those related to other pedicle screw -based devices 
and proced ures available on the market.  
Those risks/ possible adverse events include:  
(a) risks associated with undergoing surgery;  
(b) risks associated with spine surgery;  
(c) risks associated with fusion surgery of the lumbar spine; and  
(d) risks associated with the use of the Ca rboClear  Pedicle Screw System.  
The individual risks associated with each of the above groups are provided below.  
 
Risks Associated with Undergoing Surgery  
 Infection/Sepsis.  
 Development of respiratory problems, e.g. atelectasis, bronchitis, pneumonia, 
etc. 
 Haemorrhage of blood vessels and/or haematomas occlusion, seroma, edema, 
hypertension, embolism, stroke, excessive bleeding, phlebitis, wound necrosis, 
wound dehiscence, damage to blood vessels, or other types of cardiovascular 
system compromise.  
 Deep veno us thrombosis, thrombophlebitis and/or pulmonary embolus.  
 Damage to lymphatic vessels and/or lymphatic fluid exudation.  
 Reactions to the drugs or anesthetic agent used during and after surgery.  
 Ileus, gastritis, bowel obstruction or loss of bowel control or other types of 
gastrointestinal system compromise.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 76 of 117  
 
 Reactions to transfused blood . 
 Incisional pain.  
 Change in mental status.  
 Death.  
 
Risks Associated with Spine Surgery  
 Loss of neurological function ( e.g., sensory or motor), including paralysis 
(comple te or incomplete), appearance of radiculopathy, dysesthesias, 
hyperesthesia, anesthesia, paresthesia, and/or the development or continuation 
of pain, numbness, neuroma, spasms, sensory loss, tingling sensation, and/or 
visual deficits.  
 Cauda equina syndrome , neuropathy, neurological deficits (transient or 
permanent), paraplegia, paraparesis, reflex deficits, irritation, arachnoiditis, 
and/or muscle loss.  
 Dural tear experienced during surgery could result in the need for further 
surgery for dural repair, a ch ronic cerebral spinal fluid leakage or fistula, and 
possible meningitis.  
 Herniated nucleus pulposus, disc disruption or degenerative changes or 
instability at, above, or below the level of surgery.  
 Loss of or decrease in spinal mobility or function.  
 Loss o f proper spinal curvature, correction, height and/or reduction.  
 Bone fracture or bone loss or decrease in bone density, possibly caused by 
stresses shielding at, above, or below the level of surgery.  
 Tissue or nerve damage caused by improper positioning an d placement of 
implants or instruments.  
 Vascular damage due to surgical trauma or presence of the device could result 
in catastrophic or fatal bleeding. Malpositioned implants adjacent to large 
arteries or veins could erode these vessels and cause catastro phic bleeding in 
the late postoperative period.  
 Bursitis.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 77 of 117  
 
 Scar formation possibly causing neurological compromise or compression 
around nerves and/or pain.  
 Inability to resume activities of normal daily living.  
 Reproductive system compromise, including sterility, retrograde ejaculation, 
and sexual dysfunction.  
 Urinary retention or loss of bladder control or other types of urological system 
compromise.  
 Risk of radiation exposure preoperatively, during surgery and following 
operation, during follow -up sess ions ( e.g., fluoroscopy, X -Rays, and optionally 
CT scans) . 
The series of radiographs required for this study are similar to the standard of 
care for patients with similar traditional surgical procedures. The risk of any 
side effects from this low level of exposure is very small. It is estimated that 
the total millirems will be less than 200 millirems per visit (for a 4 view x -ray) 
or no more than 1300 millirems for the duration of this study. This exposure 
can be compared to the allowable annual radiation d ose for nuclear 
medicine/radiation oncology workers of 1800 millirems per year.23 The 
consequences of this radiation are small, but can include developing cancer 
later in life from the radiation.24 Radiation exposure associated with computed 
tomography (CT) scans of the lumbar spine is higher, and may approach 6 
milliSieverts, or the equivalent of approximately 730 days of natural 
background radiation (at 3 mSv/year). The consequences of CT scans are 
small, but can include developing cancer later in life, and  potential reactions to 
contrast agent.24 
 
  
                                                 
23http://www.fda.gov/RadiationEmittingProducts/RadiationEmittingProductsandProcedures/Medicallm
aging/MedicaiX -Rays/ucm175028.htm  
24http://www.fda.gov/RadiationEmittingProducts/RadiationEmittingProductsandProcedures/Medicallm
aging/MedicaiX -Rays/ucm115317.htm  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 78 of 117  
 
Risks Associated with Fusion Surgery of The Lumbar Spine  
 Graft settling/displacement . 
 Non-union (or pseudarthrosis), delayed union or mal -union.  
 Donor site pain.  
 Risks pertaining  to the use of allograft (if applicable), including infection, 
fever, incomplete bone ingrowth, delayed fusion or non -union, hypercalcemia 
or transient hypercalcemia, disease transmission and undesirable immune 
response.  
 
Risks Associated with The Use of T he CarboClear Pedicle Screw System.  
 Disassembly, loosening, bending or fracture of any or all of the implant 
components.  
 Implant migration.  
 Foreign body (allergic) reaction to the implants, debris, including possible 
staining, autoimmune disease, tumor for mation and/or scarring.  
 Pressure on the surrounding tissues or organs.  
 Pressure on the skin from component parts in patients with inadequate tissue 
coverage over the implant, possibly causing skin penetration, irritation, 
fibrosis, neurosis, and/or pain.  
 
Additional surgical intervention may be necessary to correct some of the possible 
adverse events.  Surgical intervention may be a revision surgery, a removal procedure, 
re-operation, or supplemental fixation.  
 
This list of potential risks is presented, in t he same manner, in the patient Informed 
Consent  document, in the Case Report Forms, and in the IFU (Package Insert) for the 
system.  
 
5.14.2  RISK REDUCTION MEASURES  
Risk management activities are carried following the guidelines provided in ISO 
14971 Standard ( Medical Devices – Application of Risk Management to Medical 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 79 of 117  
 
Devices ). The analysis of risks was performed using the Failure Mode and Effect 
Analysis (FMEA) in its extended version (FMECA) , in accordance ISO 14971 and 
IEC 812 (Failure Mode and Effects Analysis ).  
 
CarboFix activities, from initial design stages, are aimed at minimizing as possible 
faults, malfunctions, incidents, etc., related to the device. In order to reduce the risk of 
patient (or user) harm or a fault/damage to the device during its  usage, the following 
measures are taken:  
a. Design activities according to written design control procedures;  
b. Risk management activities, including risk analysis;  
c. Biocompatibility evaluation;  
d. Conducting pre -clinical, comprehensive bench testing and cadaveric study;  
e. Manufacturing according to quality system requirements ( e.g., production 
according to approved specifications, drawings and instructions; performing 
quality controls to incoming raw  material, following production stages, and to 
finished devices; etc.); 
f. Providing a clear Instructions for Use document (IFU) and Surgical 
Technique. Among other things, these documents include description of the 
system and its components (including figure s), indications for use and 
contraindications, possible adverse events, warnings and precautions, 
instructions regarding system preparation, surgical procedure description, 
information regarding the compatibility of the product with other devices, and 
information regarding product packaging and sterilization.  
g. Conducting additional validations and verifications, as applicable, such as 
sterilization  validation.  
 
The following paragraphs specifically address the risks indicated above, and the 
measures by whic h those potential risks are minimized.  
 
A. Risks Associated with Undergoing Surgery  
General operative -related complications (such as infection/sepsis, bleeding/vascular 
injury, respiratory and cardiac complications, anesthesia, wound complications and 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 80 of 117  
 
pain, etc., as listed above ) are expected to be similar in nature and not in higher rates 
compared to those seen with other pedicle screw systems, as the surgical procedure is 
the same.  
As the implantation procedure is similar to that used for other pedicle scre w system 
implantation, using similar surgical instruments, and as cleared interbody fusion 
device is used, no additional/special hazards are expected to rise from the operation 
procedure itself.  
It is noted, that the implantation procedure and the perform ance of the surgical 
instruments were also evaluated during cadaveric study.  
 
In addition, the CarboClear System is currently under multi -center study conducted 
out-of-the-US. So far , 47 patients were already treated with the system, with a follow -
up durat ion of up to over one year (40 of which had diagnosis that compl ies with the 
indications proposed in the IDE ( i.e., DDD patients with up to Grade I 
spondylolisthesis). The following adverse event, which may be categori zed as related 
to undergoing surgery, was reported in the said study:  
In one patient, f ever was developed following uneventful operation and discharge (5 
days following surgery). CT images revealed well -positioned implants with no root 
irritation. The surgical wound was healed, with no infecti on. Blood cultures were 
negative. The patient was hospitalized and treated with intra -venous antibiotics for 
three days, and was then discharge from the hospital with additional 2 weeks of 
antibiotics. Fever was probably related to pneumonia. The patient heale d and is doing 
well.  
 
B. Risks Associated with Spine Surgery  
Complications associated with spine surgery (as listed above ) are expected to be 
similar in nature and not in higher rates compared to those  seen with other pedicle 
screw systems, as the implant c omponents design and dimensions, and the surgical 
procedure for their implantation (as well as the use of the cleared intervertebral fusion 
device), are similar.  
As the implantation procedure is similar to that used for other pedicle screw system 
implanta tion, using similar surgical instruments, no additional/special hazards are 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 81 of 117  
 
expected to rise from the spinal procedure in comparison to other, similar spinal 
surgeries.  
It is noted, that the implantation procedure and the performance of the surgical 
instruments were evaluated during cadaveric study.  
Regarding the risk of radiation exposure, no additional risk of radiation exposure is 
expected prior to -, during the implantation of the CarboClear device as well as during 
follow -up sessions, compared to radiation exposure associated with similar spinal 
implants that are being investigated in clinical studies. The risk of radiation exposure 
during implantation procedure is also expected to be the same as that for cleared 
pedicle screw systems. It is expect ed, though, that subjects participating in a clinical 
study for spinal implants may undergo additional imaging at follow -up sessions and 
thus the risk of radiation exposure may be slightly higher for this population 
compared to patients undergoing spinal s urgery with a cleared device.   
 
In addition, data from the on -going OUS clinical investigation (for the 40 patients that 
comp ly with the indication s for the proposed IDE study ) supports the similarity 
between the CarboClear spinal  surgery parameters with t hose of other, similar 
devices:  
Operation Time  - Average total operation time recorded during the said 40 surgeries 
with the CarboClear System was 115.1 minutes (±23.4 minutes), ranging from 72 to 
185 minutes. Operation time reported for the surgeries carr ied to date is similar to that 
reported by others for this type of surgeries (for example, Kim  et al. 25 report average 
operation time of 196 minutes, and Dimar et al. 1 – 174 minutes).  
Blood Loss  - Average blood loss recorded during the 40 surgeries was 3 79.4 cc 
(±125.6 cc),  ranging from 200 cc to 600 cc. Blood loss reported for the surgeries 
carried to date is similar to that reported by others for this type of surgeries (for 
example, Dimar et al. 26 report average blood loss of 448.6 mL, and Kang at al . 27 - 
512.5 mL).  
                                                 
25  Kim KK, Lee SH, L ee YH, Bae SC, Suk KS, Clinical Outcomes of 3 Fusion Methods through the 
Posterior Approach in the Lumbar Spine. Spine 2006; 31 (12): 1351 – 1357.  
26  Dimar JR, Glassman SD, Burkus JK, Pryor PW, Hardacker JW, Carreon LY.  Two-year fusion and 
clinical outcomes in 224 patients treated with a single -level instrumented posterolateral fusion with 
iliac crest bone graft. The Spine Journal  2009;9:880 –885. 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 82 of 117  
 
Fluoroscopy Time - Average fluoroscopy time recorded during the 40 surgeries was 
38.7 seconds (±18.9 seconds), ranging between 20 and 100 seconds. Fluoroscopy time 
reported for the surgeries carried to date is similar to that reported by oth ers for this 
type of surgeries (for example, Jones et al. 28 report fluoroscopy time of 1.4 minutes 
(i.e., 84 seconds) per case or 0.33 minutes per screw, in a series of 140 patients who 
underwent pedicle screw fixation; Mulconrey 29 reported mean fluoroscop ic time of 
1.74 minutes (104.4 seconds) with lumbar spine instrumentation).  
 
The on -going clinical investigation with the CarboClear device also supports the 
proper visualization of implant components, either during operation or at follow -up 
period. This m inimizes the risk of pedicle screws malpositing, and subsequent adverse 
events such as nerve tissue injury  and possible additional surgical intervention. Pre -
clinical evaluation of implant components was conducted during cadaveric study, 
using three imagin g modalities (X -Rays, CT and MRI).     
In addition, the following adverse event , that  may be categorized as related to spinal 
surgery , was reported in the OUS  study (for the 40 DDD patients):  
About 1 week post -operation the patient complained of radicular pain, with no motor 
deficiency and no fever. CT demonstrated mild compression and edema, with no 
nerve root irritation. The implants seemed well positioned and intact. The patient was 
re-operated (exploratory surgery), revealing mild compression at  the sur gery site. The 
instruments were well positioned and stable. During this surgery additional 
decompression at one level above the surgery  was performed. All symptoms resolved 
after second operation, with improvement in pain and functionality parameters at 3 
months follow -up as compared to pre -operation data.  
                                                                                                                                            
27  Kang J, Howard A, Hilibrand A, Yoon ST, Kavanagh E, Boden S. Grafton and Local Bone Have 
Comparable Outcomes to Iliac Crest Bone in Instrumented Single -Level Lumbar Fusions. Spine  
2012;37(12):1083 –1091 . 
28  Jones DP, Robertson PA, Lunt B, Jackson SA, Radiation exposure during fluoroscopically assisted 
pedicle screw insertion in the lumbar spine. Spine  2000; 25 (12): 1538 -41. 
29 Mulconrey DS , Fluoroscopic Radiation Exposure in Spinal Surgery: In Vivo Evaluation for 
Operating Room Personnel. J Spinal Disord Tech.  2013 Nov 7 [Epub ahead of  print].  
 
 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 83 of 117  
 
The event was categorized as not related to the device, and possibly related to the  
procedure.  
 
C. Risks Associated with Fusion Surgery of The Lumbar Spine  
Complications associated with lumbar fusion include, on top of spinal surgery risks 
indicated above, graft settling/displacement, non -union (pseudarthrosis), delayed 
union or mal -union, and donor site pain.  Additional risks may be associated with  the 
use of allograft (if used), as listed above . It is noted, that the CarboClear device may 
be implanted with autogenous and/or allogenic bone graft . 
 
Those complications are expected to be similar in nature and not in higher  rates 
compared to those  seen with other pedicle screw systems, as the surgical procedure 
and instruments used for fusion, as well as the cleared interbody fusion device and 
bone graft materials, are similar.  
 
Data from the on -going OUS clinical investigation accumulated so far (for the 40 
patients that comp ly with the indications for the proposed IDE study) support the 
safety and effectiveness of the CarboClear System and indicate the following fusion 
rates:  
 At 6 months  (1 level): 25/26 patients (96.2%);  
 At 12 months (1 level): 3/3 patients (100%);  
 At 6 months (2 levels): 1/1 (100%).  
It is noted, that comparative bench testing conducted for the system (as detailed in the 
Investigator Brochure ) supports  the similar perfo rmance of the system and cleared, 
metal, pedicle screw systems in term s of both test results and failure modes. In 
particular, with respect to the ability of the CarboClear rods to provide for adequate 
stiffness to support fusion - long-term stability and  stiffness of the CFR -PEEK rods 
were successfully evaluated in static and dynamic tests conducted for the entire 
implant construct, as well as in 4 -point bending test and creep test conducted for the 
rods.  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 84 of 117  
 
As it is postulated, based on all the above, that  the risk of non/delayed/mal fusion 
would not be at a higher rate than that seen for other cleared, rigid, pedicle screw 
systems, it is expected that the risk of re -operation due to those risks will also be at 
similar rate as the rate reported for other ri gid pedicle screw systems.  
 
D. Risks Associated with The Use of The CarboFix Pedicle Screw System   
In general, risks related to the use of the device are mitigated by the following 
measures:  
 Implant components are similar in design and dimensions to those of other, 
cleared, rigid pedicle screw systems. As with other pedicle screw systems, the 
CarboClear components allow the surgeon to build an implant construct to fit 
the patient’s anatomical and physiological requirements ( e.g., the screws and 
rods are provided in various dimensions, the pedicle screws comprise a 
polyaxial head, and the rods are provided either straight or curved, all of which 
provide for an implant construct that meets the an atomical needs of the 
patient);  
 The surgical instruments of the system and the surgical procedure are similar 
to those used with other, cleared, pedicle screw systems;  
 Extensive biomechanical study was performed, as summarized below and 
detailed in the Inv estigator Brochure , with results and failure modes equivalent 
to those of the predicate devices;  
 Supportive clinical data are available from OUS clinical trial, as summarized 
in the Investigator Brochure ; 
 Training of the study investigators ;  
 Providing IFU  (Package Insert) and  Surgical Technique documents, as 
detailed below;  
 The use of the system is limited to only experienced spinal surgeons with 
specific training in the use of this system ; 
 The system is designed, processed, assembled, tested, and packaged  according 
to the Company approved procedures. Wherever required, processes are being 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 85 of 117  
 
verified and validated according to the Company approved procedures and 
international standards.  
The specific risks are detailed below, with the manner of their mitigatio n. 
 
Implant Mechanical Failure - Disassembly, Loosening, Bending , Fracture  or Migration  
The CarboClear device was tested in a comprehensive in-vitro  study and a cadaveric 
study, to validate its design and to assess its performance ( e.g., bone purchase and 
function) and integrity (of the components and construct). Pre -clinical testing included 
the following tests:  
 Static axial compression bending test (ASTM F 1717)  
 Static torsion test (ASTM F 1717)  
 Fatigue axial compression bending test (ASTM F 1717)  
 Fatigue  lateral bending -axial rotation test  
 Wear debris evaluation following fatigue testing (ASTM F 1877)  
 Axial gripping capacity test (ASTM F 1798)  
 Flexion -extension moment test (ASTM F 1798)  
 Axial torque gripping capacity test (ASTM F 1798)  
 Pull-out test (ASTM  F 2193, ASTM F 543)  
 Rod 4 -point bend test (ASTM F 2193)  
 Titanium shell shear test (ASTM F 1044)  
 Rod creep test  
 Cadaveric study  
Where applicable, tests were conducted in a comparative manner, to FDA -cleared 
predicate devices (rigid pedicle screw systems) . Bench testing demonstrated 
substantial equivalent results and same failure modes. Please refer to the Investigator 
Brochure , for detailed  description of the said tests.  
Various tests, and in particular fatigue tests, were performed to verify no failure of the 
implant ( e.g., breakage, deformation, or disassembly) will occur prior to fusion. In 
fatigue axial compression bending test, the device construct successfully completed 
five million cycles under a load of 300 N, corresponding to 83% of its ultimate load. 
Lateral bending -axial rotation fatigue tests, conducted to further  support the system 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 86 of 117  
 
mechanical properties and the equivalency to rigid, metal, pedicle screw systems , 
demonstrated the device completed 5x106 cycles at high moment of at least 8.5 Nm 
with no failure.  
Macroscopic and microscopic examination  of the device s following  the said fatigue 
tests indicated no plastic deformation of the rods. No scarring formation was detected. 
Wear debris analysis following fatigue tests indicated that only smal l amount of CFR -
PEEK debris was generated following successful completion of 5x106 fatigue cycles at 
relatively high loads and /or moments.   
 
Regarding loosening/disconnection  of implant components - the CarboClear device is 
designed to prevent movement bet ween its components, immediately upon locking. 
The rod is secured to the screw using a taper locking element, that accommodates the 
rod and is introduced within the screw tulip. Loosening/disconnection of components 
was assessed in several tests following the guidelines set in ASTM F 1798, which 
were designed to evaluate the interconnection mechanism of the device. Additional 
tests which evaluated the entire CarboClear construct, including fatigue tests, also 
demonstrated that the locking mechanism of the s ystem is effective and comparative to 
cleared rigid pedicle screw systems.  
 
It is noted, that the screw  is provided with a thin titanium shell, thus bone -implant 
interface is similar to that of other, cleared, pedicle screws.  
Shear test was successfully conducted to verify the integrity and connection of the 
titanium shell to the CFR -PEEK screw.  
As for implant migration  - pullout tests performed to the  CarboClear pedicle screws 
demonstrated that their pullout strength is simil ar to that of cleared predicate devices.  
 
Nonunion, Delayed Union or Malunion   
Long -term stability and stiffness of the CFR -PEEK rods (adequate stiffness to achieve 
fusion) were evaluated in static and dynamic tests conducted for the entire construct 
(i.e., four screws and two rods), as well as in 4 -point bending test and creep test 
conducted for the rods.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 87 of 117  
 
The results of the said tests indicated excellent fatigue properties and similar stiffness 
as compared to titanium pedicle screw constructs and titanium  rods.  
The results obtained for the creep test, following more than five weeks  under a high 
continuous load of 450 N and at a temperature of 70° C (conditions which simulate a 
year at 37° C and extreme loading), demonstrate no plastic deformation to any of  the 
rods and high creep resistance.   
 
Implant Malposition  
Similarly to implantation of other pedicle screw systems, the surgical procedure is 
monitored radiographically, to verify, among other things, proper location of the 
screws and final construct po sitioning. Radiographic evaluation is also performed 
post-operatively.  
The implant components of the CarboClear System are made of radiolucent material - 
CFR -PEEK, with metal radiopaque markers intended to enable implant visualization 
under imagine. Espec ially, the threaded portion of the pedicle screws is encased 
within a thin layer titanium shell . The titanium shell mark the borders of the screw 
thread and distal tip, thus facilitating proper insertion of the screws under fluroscopy  
visualization, as well as monitoring their location ( e.g., relative to nerve tissue) and 
integrity post -operatively. The other implant components comprise a tantalum marker.   
In accordance with FDA recommendation, the Company has conducted cadaveric 
study in a human spine, demonstrating the visualization of the CarboClear implants 
using the following imaging modalities: MRI, CT and X -rays.  
It is emphasized, that due to the relative small metal content, the screws do not 
interfere with CT and MRI imaging while allowing screw visualization under X -rays.  
In addition, the implantation procedure and the performance of the surgical 
instruments were also evaluated during cadaveric study.  
 
Foreign Body Reaction to the Implant  
The implant components are made of CFR-PEEK (Ultra Reinforced -PEEK -
OPTIMA® (Endolign), by Invibio), with radiopaque  markers.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 88 of 117  
 
The screw threaded portion is encased within a thin shell made of pure titanium 
(conforming to ASTM F 67). The other CFR -PEEK components include a tantalum 
(per ASTM F  560) marker, embedded within the CFR -PEEK during molding process. 
The said materials are acceptable for use in long -term implants and exist in other, 
cleared spinal implants (including their combination).  
In addition, the different manufacturing processe s (e.g., compression molding) do not 
include the use of any additive, releasing agent, etc. For a detailed biocompatibility 
evaluation, please refer to the Investigator Brochure .  
As indicated before, evaluation of wear debris generation was conducted foll owing 
successful completion of five million fatigue cycles at relatively high loads and 
moments, as well as following device failure. Analysis of collected material 
demonstrated that only a small amount of CFR -PEEK debris was generated. The 
description of the wear debris tests is  provided in the Investigator Brochure . 
 
Infection (Non -Sterile Device)  
Regarding the risk of infection due to non -sterile device - the implants will be 
supplied sterile (by moist -heat steam) and labeled for single use. The multi -use 
surgical instruments will be supplied non -sterile, to be steam sterilized by the user. 
The steam sterilizations for the system components were validated to assure SAL of 
10-6, and bioburden tests are conducted periodically.  
Information regarding the sterilization of the implants and the cleaning and 
sterilization of the reusable surgical instruments is provided in the Investigator 
Brochure.  
 
Regarding the ongoing OUS study - it is emphasized, that no device -related adverse 
events or device malfunc tions were reported  in any of the 47 patients implanted with 
the system . No failure was observed to any of the components implanted (about 180 
pedicle screws (and locking elements), with about 90 rods for all 47 patients 
operated).  
In addition, as indicat ed earlier, f usion  - determined by X -Ray images indicating 
continuous fusion in between transverse processes and /or facet joints (AP and lateral 
X-Rays) – was indicated in the following rates  (for the 40 DDD patients; please note 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 89 of 117  
 
that for part of the patie nts, evaluation of translational and angular motion using 
flexion/extension radiographs was also conducted) : 
 At 6 months (1 level): 25/26 patients (96.2%);  
 At 12 months (1 level): 3/3 patients (100%);  
 At 6 months (2 levels): 1/1 (100%).  
 
The on -going clinical investigation with the CarboClear device also supports the 
proper visualization of implant components, either during operation or at follow -up 
period.  Also , no allergic reaction to the implant was reported.  
 
As it is postulated, bas ed on all the above, that the risk of device 
breakage/loosening/disassembly/migration; non/delayed fusion; or foreign body 
reaction to the device, would not be at a higher rate than seen for other cleared, rigid, 
pedicle screw systems, it is expected that the risk of re -operation due to th ese risks 
will be at similar rate as the rate reported for other pedicle screw systems.  
 
On top of the above, a ll the operating instructions are described in the IFU and  
Surgical Technique documents (refer to Appendix A). The intended use, as well as 
inclusion/exclusion criteria for the clinical trial, are defined and detailed. The IFU 
(Package Insert) and Surgical Technique describe the safety  and protective measures 
required when handling the system as well as providing a description of the system, 
all the procedures regarding system preparation, and operation procedures. Possible 
adverse events are described in the IFU. Relevant packing and sterilization data are 
also provided in the IFU  as well as in the Company's Instr umentation Handling 
Instructions. The IFU  and Surgical Technique provide specific information relating to 
implant selection and patient selection.  
Safe use of the system with other devices is established by using items that comply 
with the requirements se t in the Surgical Technique/IFU,  where applicable, and in the 
manner detailed in the Surgical Technique . Reference is made in the Surgical 
Technique to the IFU and vice versa .  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 90 of 117  
 
Please note, that the different components of the system (including surgical 
instruments), as well as the Surgical Technique and IFU, are designed in a similar 
manner, and include similar information to that provided with other pedicle screws 
systems available on the market. This further contributes to reducing the possibility of 
new hazards related to use of the system, and the risk of insufficient or inadequate 
information provided.  
The IFU and Surgical Technique document s are reviewed prior to their release, and 
are approved according to the Company 's procedures.  
The device labels are also reviewed prior to their release, and are approved according 
to the Company 's procedures. Wherever applicable , warnings regarding single use of 
components and the sterility of components are provided. The name of the 
component/content list, and catalogue and lot number s are  indicated on the items’ 
labels as well.  
 
5.14.3  POTENTIAL BENEFITS  
In general, patients may not experience any direct benefits.  
Based on the performance of other cleared pedicle screw systems that have 
successfully relieved symptoms of  degenerative disc disease, and clinical experience 
with the investigational device outside the United States, there is reason to believe 
that the CarboClear Pedicle Screw System could also relieve DDD symptoms.   
 
5.14.4  ADVERSE EVENTS  
5.14.4.1  Definitions  
Adverse Event (AE)  
Any untoward medical occurrence, unintended disease or injury, or untoward clinical 
signs in subjects, users or other persons, whether or not related to the investigational 
medical device (including events related to the investigational medical device ; and 
events related to the procedures involved).  
 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 91 of 117  
 
Serious Adverse Event  
Defined as one of the following events:  
a. Death;  
b. Serious deterioration in the health of the subject, that either resulted in:  
 a life -threatening illness or injury, or  
 a permanent impairment of a body structure or a body function, or  
 in-patient or prolonged hospitalization, or  
 medical or surgical intervention to prevent life -threatening illness or 
injury or permanent impairment to a body structure or a body function,  
c. Event that led to fetal distress, fetal death or a congenital abnormality or birth 
defect.  
Note : Planned hospitalization for a pre -existing condition, or a procedure required 
by the protocol, without serious deterioration in health, is not considered a 
serious adverse ev ent. 
 
Adverse Device Effect  
Adverse event related to the use of an investigational medical device (including 
adverse events resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfun ction of the 
investigational medical device, and any event resulting from use error or from 
intentional misuse of the investigational medical device ).  
 
Serious Adverse Device Effect (SADE)  
Adverse device effect that has resulted in any of the consequence s characteristic of a 
serious adverse event.  
 
Device Deficiency  
Inadequacy of a medical device with respect to its identity, quality, durability, 
reliability, safety or performance (including malfunctions, use errors, and inadequate 
labeling).  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 92 of 117  
 
Unanticipated Adverse Device Effect  
Unanticipated adverse device effect means any serious adverse effect on health or 
safety or any life -threatening problem or death caused by, or associated with, a 
device, if that effect, problem, or death was not previo usly identified in nature, 
severity, or degree of incidence in the investigational plan or application (including a 
supplementary plan or application), or any other unanticipated serious problem 
associated with a device that relates to the rights, safety, or welfare of subjects.  
 
5.14.4.2  Assessing a nd Reporting  of Adverse Events  
All adverse events, adverse device effects and  device deficiencies (collectively: 
“Adverse Events”) will be documented using the relevant Adverse Events Report 
Forms. In addition, each subject will be questioned about Adverse Events at each 
follow -up visit. Adverse Events discovered during a routine f ollow -up will be 
documented additionally on the relevant follow -up CRF.  
Adverse Events occurring  during the study will be treated by established standards of 
care that will protect the life and health of the study subjects.  
Signs and symptoms of each Adve rse Event should be described in detail and include 
start and stop dates, intensity, correlation with investigational device, action taken and 
outcome.  
The Investigator shall evaluate and document the following:  
1. whether any Adverse Events have occurred;  
2. the nature of the event;  
3. date of A dverse Event onset and duration;  
4. seriousness of the event ( serious , moderate, mild /minor);  
5. relation to the investigational device (not related, possibly related, definitely 
related) ; 
6. Adverse Event  outcome and the course t aken to reach the outcome . 
The report of AEs based on specific type of event will be classified according to the 
following AE terms, listed in the table below, and in accordance with FDA list of risks 
applicable for pedicle screw spinal systems ( FDA’s Exec utive Summary, Table 11 ). 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 93 of 117  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In addition, as per the FDA recommendation, the adverse events will be further 
classified according to the following Adverse Events table (as applicable to this study, 
e.g., no control group):  
 
 ADEVERSE EVENTS  
Implant Malposition  
Implant Loosening  
Device Breakage  
Construct Disassembly  
Bone Fracture  
Graft Settling/Displacement  
Loss of Correction  
Pseudoarthrosis  
Bleeding/Vascular Injury  
Neurologic Injury  
Back/Leg Pain (Radiculopathy)  
Dural Tear/CSF Leak  
Wound problems   
Infection/Sepsis  
Skin Irritation  
Cardiac  
Respiratory  
Gastrointestinal  
Reoperation/Revision  
Death  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 94 of 117  
 
 
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
All Adverse Events1               x 
(x %)  x x 
(x %)  x 
Operative Site/Implant/Spine Surgery Focused Events  
 (Includes Perioperative Systemic Events Related to the Operative Site Occurring within 6 weeks of any spine procedure (initia l or subsequent) at the index or 
adjacent level)  
                   
Implant (Total)                    
Breakage                    
Loosening                    
Migration                    
Malposition                    
Subsidence                    
                   
Lumbar Spinal Event Target Level  
 (Total)                    
Spinous Process Bone Erosion                    
Spinous Process Bone Reactive 
Change / Scleros is               
    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 95 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Spinous Process Fracture                    
Facet Joint Degenerative Changes  
(Weishaupt)                    
Other (please specify in footnote)£                    
                   
                   
 
                   
Lumbar Spinal Event Adjacent 
Contiguous Level                    
                   
Lumbar Spinal Event Adjacent 
Non-Contiguous Leve l               
    
                   
Nonoperative Control Group Event                    
                   
Nonunion (pseudarthrosis)                    
                   
Intraoperative Events  
Total                    
Anatomic/Technical Difficulty                    
Lumbar –Initial Surgery                    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 96 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Lumbar – Subsequent Surgery                    
Device Unable to be Implanted                    
Intraoperative Device Revision                    
Dural Tear/Leakage                    
Intraoperative Vascular Injury                    
Anesthesia, Airway,Ventilation                    
Visceral Injury                    
Intraoperative Neurologic Injury                    
Intraoperative hypotension                    
Blood transfusion                    
Excessive blood loss                    
Major allergic reaction                    
Other (please specify in footnote)                    
                   
                   
                   
                                                                             Perioperative Systemic Events (Occurring ≤ 6weeks of operation)  
Total                    
Deep vein thrombosis                    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 97 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Pulmonary embolism                    
Retrograde Ejaculation                    
Anesthesia, Airway,Ventilation                    
Cardiac arrest/failure/arrhythmia                    
Myocardial infarction                    
Dysphagia                    
Dysphonia                    
Gastrointestinal bleeding                    
Pneumonia                    
Pressure sores                    
Urinary tract infection                    
CSF leak/meningocele                    
Sepsis unrelated to operative site                   
Other (please specify in footnote)                    
                   
Post-Surgical Spinal Injections / Nee dle Based Procedures /Rhizotomies / Spinal Stimulators  
Total                    
Epidural                    
Nerve root block                    
Facet Joint injection                    
Medial branch block                    
Sacroiliac injection                    
Trigger point                    
Rhizotomies                    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 98 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Spinal Stimulators                    
Other (please specify in footnote)                    
                   
Incision -Related, Non -Infectious (Lum bar) 
Total                    
 Posterior  Lumbar  
Study Surgical Incision                
    
Dehiscence                    
Hematoma                    
Hematoma Evacuation                    
CSF Leakage                    
Posterior Lumbar  Non -Study 
Incision (Specify AE type)                
    
                   
Infection  
Total                    
Superficial Wound – Posterior      
Lumbar Study Incision                
    
Deep Wound – Posterior Lumbar   
Study Incision                
    
Visceral / Organ space (Index level)                    
Superficial Wound – Posterior      
Lumbar Non -Study Incision                
    
Deep Wound – Posterior Lumbar                        
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 99 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Non-Study Incision  
Visceral / Organ space (Non -Index 
Spinal level)                
    
   Other (i.e., cellulitis, erythema)                    
                   
                   
                   
                   
Subsequent Surgical Interventions (Lumbar ) 
Total                    
Reoperation: Index level                    
Reoperation: Adjacent Contiguous 
Level                
    
Reoperation: Index level and 
Adjacent Con tiguous Level                
    
Reoperation: Adjacent Non -
Contiguous Leve l               
    
                   
Neurological†  
Neurological                    
Total (Upper extremity)                    
Upper Extremity – Sensory                    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 100 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Upper Extremity – Motor                    
Upper Extremity – Reflex                    
Total (Lower extremity)                    
Lower Extremity – Sensory                    
Lower Extremity – Motor                    
Lower Extremity – Reflex                    
Spinal Cord / Cauda Equina      
Disturbance                
    
Upper extremity nerve   
compression (i.e. ca rpal tunnel)                
    
Subjective*                    
Non-specific or Other**                    
                   
                   
                   
Pain Events  
Pain Events Considered as Spine -Related  
Cervical Spine/Upper Extremity  
Pain (Total)                
    
Cervical Pain (Cervical Region)                    
Upper Extremity Pain                    
Combined Cervical and Upper   
Extremity Pai n               
    
Thoracic Pain (Thoracic Region)                    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 101 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Lumbar Spine/Lower Extremity 
Pain (Total)               
    
Low Back Pain (Lumbar Region)                    
Lower Extremity Pain                    
Combined Low Back and Lower  
Extremit y Pain  
               
    
Other (Non -Spinal) Pain  
Total                    
Upper Extremity                    
Torso/Mediastinal                    
Lower Extremity                    
Headache                    
Abdominal                    
Pelvic                    
Other (please specify in footnote)                    
Musculoskeletal Events  
Total                    
Cervical                    
Thoracic                    
Lumbar                    
Upper Extremity                    
Lower Extremity                    
Sacroiliac                    
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 102 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
Other (please specify in footnote)                    
Systemic Events (Total, Includes Systemic Events Occurring  Within 6 Weeks of Index Surgery)  
Total                    
Respiratory                    
Cardiac                    
Gastrointestinal                    
Infection (Systemic)                    
Cancer                    
Dermatologic                    
Urogenital                    
Ear, Nose, Throat                    
Hematologic                    
Endocrine                    
Hepatobiliary                    
Immunologic                    
Metabolism/Nutrition                    
Gynecologic                    
Opthalmologic                    
Psychological                    
Pregnancy                    
Surgical Procedure: Non -Spinal                    
Wound Infection (other f1spinal 
region: thoracic, cervi cal)                   
Wound Infection (non -spine related                   
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 103 of 117  
 
 Surgery 
to 
Discharge  Discharge  
to Week 6  Week 6  
to Month 3  Months  
3 to 6  Months  
6 to 12  Months  
12 to 18  Months  
18 to 24  Investigational  
group  Control  
Group  
Adverse Event Category  I C I C I C I C I C I C I C #Subjects  
(% of xx)  Total  
Events  #Subjects  
(% of xx)  Total  
Events  
incision)  
Incision -Related, Non -Infectious 
(other spinal region: thoracic, 
cervical)                
    
Incision -Related, Non -Infectious  
(non-spine related inc ision)                    
    Spinal Event Thoracic                    
    Spinal Event Cervical                    
Other (please specify in footnote)                    
Death                    
                   
Totals                    
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 104 of 117  
 
Classification of Adverse Events by their seriousness and relationship to the 
investigational device shall be performed according to the following definitions.  
Seriousness of Adverse Event  
 Serious Adverse  Event  – an undesirable event that is fatal or life -threatening, 
or serious deterioration in the patient health that results in disabling 
(permanent impairment) or which necessitates prolonged hospitalization or 
medical or surgical intervention to prevent said life -threatening illness/injury 
or permanent impairment. Examples of serious adverse events are nerve root 
injury leading to significant and permanent paralysis, and vascular damage to 
major vessel.  
 Moderate  Adverse  Event  - an undesirable event that does not fall into any of 
the serious adverse event definitions, and that may cause non -severe 
deterioration in the patient health (without significant permanent harm); 
moderate adverse event may require medical or minimal invasiv e surgical 
intervention or prolonged hospitalization. Examples of moderate adverse events 
are seroma or hematoma that mandate drainage, or dehiscence mandating 
revision of wound.       
 Minor Adverse Event  – an undesirable event that did not result in any of the 
serious - or moderate adverse event outcomes, that is transient and does not 
lead to permanent disability or mandating prolonged hospitalization, invasive 
intervention, or prolonged medical treatment. Examples of minor adverse 
events are post -operative fever that resolved spontaneously, or wound problem 
that does not mandate drainage or surgical intervention.   
 
Device Relatedness  
An assessment regarding the  causal  relationship between the investigational device 
and an adverse event (device relate dness) should result in classifying the adverse 
event as Definitely  Related -, Possibly  Related -, or Unrelated  to the investigational 
device, as hereby described.  
 Definitely  Related  - The adverse event  is clearly  related  to the investigational 
device, and n o alternative cause is present. Such events may be due to device 
malfunction or direct injury of the device to the surrounding tissue.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 105 of 117  
 
 Possibly  Related  - There is a reasonable possibility that the adverse event may 
have been caused by or is linked in a significant way to the investigational 
device, but an alternative cause is present.  
 Unrelated  - The adverse event is  clearly  not related to the investigat ional 
device, and an alternative cause is present. Such events may be associated with 
the surgery and general anesthesia or hospitalization, e.g., not related to the 
anatomic surgical site.     
 
In addition, an independent Clinical Events Committee (CEC) w ill be established, to 
review all Adverse Events and determine the following:  
a) Appropriate category for Adverse Events;  
b) Severity, including whether or not the event should be classified as life -
threatening;  
c) Relationship to the device;  
d) Relationship to th e procedure.  
The CEC will be composed of three  members, US orthopedic surgeon s, experienced 
in lumbar spinal fusion and pedicle screws fixation, who had conducted in the past 
similar clinical studies and similar adverse events evaluations.  
 
All Adverse Eve nts shall be reported to the Sponsor at: Fax: +972 -9-9548939; Tel: 
+972 -9-9511511; E -mail: hila@carbo -fix.com. This shall be done as soon as possible 
and no later than 5 working days after the event was first  discovered. In case of a 
verbal report, a writt en notification, using the relevant CRF ( Adverse Events Report 
Form ), shall be followed within 5 calendar days.  
Serious adverse events, serious adverse device effects, and device deficiencies that 
could have led to a serious adverse device effects should b e reported to the Sponsor 
within 24 hours after knowledge to the Investigator or any study -related study center 
staff. Verbal report shall be  followed by a detailed written notification within two 
calendar days, using the relevant form in the CRF.   
Language of the report s shall be English .  
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 106 of 117  
 
The Sponsor is responsible for the classification of Adverse Events and ongoing 
safety evaluation of the clinical investigation, and shall review the Investigator's 
assessment of all Adverse Events and determine and document in writing their 
seriousness an d relationship to the investigational device.  
In case of device deficiency, the Sponsor shall determine and document in writing 
whether it could have led to a serious adverse device effect . 
The Investigator shall supply the Sponsor, upon Sponsor's request , with any additional 
information related to the safety reporting of a particular event.  
 
The Sponsor shall report  to the Institutional Review Board (IRB ), or ensure the 
reporting by the Investigator, of serious adverse events, serious averse device effect s, 
and device deficiencies that could have led to a serious adverse device effect, if 
required by national regulations or by the IRB/EC. Where required, the Sponsor is 
responsible for reporting such events to the relevant regulatory authorities.  
 
5.15 INFORMED CONSENT  
Each subject enrolled into the study must give a written and signed informed consent 
to participate in the study, prior to entrance into the study .  
Each subject must be informed about the investigation, and must sign and date, prior to 
any procedu re specific to the clinical study applied to him/her, an Informed Consent 
Form, acknowledging that participation is voluntary and that the follow -up visits are 
essential to complete data collection. The Investigator shall also sign and date the Form.   
The Investigator will carefully explain the research nature of the study to the subject, 
avoiding any coercion or undue influence on the subject to participate the study.  
A copy of the signed Informed Consent Form will be given to the subject; the 
Investigat or shall  retain an original copy.  
The IRB must approve the Informed Consent Form used.  
 
The Informed Consent materials are provided in Appendix E. 
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 107 of 117  
 
5.16 CASE REPORT FORMS  
The data reported on the Case Report Forms (CRF) shall be derived from source 
documents and be consistent with these source documents; any discrepancies shall be 
explained in writing.  
Source data is all information, original records of clinical findings, observations, or 
other activities in a clinical study necessary for the reconstruction and evaluation of the 
study. Source data are contained in source documents.  
Examples of these original documents and data records include hospital records, 
clinical and  office charts, laboratory notes, memoranda, patients’ evaluation checklists, 
recording media such as DVD, x -rays, patient files, and records kept at the laboratories.  
The Investigator shall assure the accuracy, completeness, legibility and timeliness of t he 
data reported to the Sponsor on the CRFs and in all required reports. Where copies of 
the original source document as well as printouts of original electronic source 
documents are retained, these shall be signed and dated by a member of the 
investigatio n site team with a statement that it is a true reproduction of the original 
source document.  
All data requested on the CRFs must be recorded. Missing data shall be explained. The 
CRFs shall be filled in English, and signed and dated by the Investigator. An y change 
or correction to data reported on a CRF shall be dated, initialed and explained if 
necessary, and shall not obscure the original entry.  
 
The Case Report Forms (as well the Patient Questionnaires) are provided in 
Appendix F. 
 
5.17 CONFIDENTIALITY  
The p rivacy of each subject participating in the study and confidentiality of his/her 
information shall be preserved. The patient’s full name will be removed from any 
study document to maintain confidentiality . Subject number and initials will identify 
patients . Data shall be secured against unauthorized access.   
 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 108 of 117  
 
5.18 MONITORING  
Monitoring of the study will be performed according to the Sponsor’s approved 
monitoring procedures.  
The Sponsor  shall appoint a monitor to oversee the clinical study. The monitor shall 
be qualified by training and experience to monitor clinical studies, and shall be 
knowledgeable on the use of the investigational device, as well as the relevant 
regulation and requirements, the investigational plan, and the informed cons ent 
process. Training of the monitoring shall be documented in the Sponsor 's files.  The 
monitor may be an employee of the Sponsor or an independent contractor consultant.  
The Sponsor, together  with the monitor, will set a specific plan for the conduction of 
monitoring activities and schedules. This plan may be modified during study 
progression as deemed necessary by the Sponsor and monitor, based on the monitor 
periodic site visits/communication reports . 
 
Prior to initiation of the study , the monitor will visit or otherwise contact each site of 
the clinical investigation and will assure that the Investigator:  
1. has adequate qualifications;  
2. understands the investigational status of the system and the investigational 
plan;  
3. understands and accepts the obligations related with conducting the clinical 
investigation and the requirements set by the applicable regulations;  
4. understands and accepts the obligation to obtain IRB approval prior to 
initiation of the study and the obliga tion to notify the Sponsor of any changes 
to that approval status;  
5. signed the Investigator Agreement and forwarded a signed copy to the 
Sponsor;  
6. understands and accepts the obligation to obtain an informed consent 
according to the relevant regulations;  
7. has the adequate number of subjects suitable for the project, adequate 
facilities and resources, and sufficient time to carry the responsibilities of an 
investigator ; and  
8. was (with his/her team) trained for the use of the investigational device ; 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 109 of 117  
 
9. understand s the importance of a timely report of any adverse events.  
 
The monitor will be responsible for initiating the study  and verifying that all the 
protocol and regulatory authority requirements are met prior to the initiation of the 
study ( e.g., the study proto col and other study documents were received and are 
understood to the investigator and his/her staff;  the investigator and his/her team were 
trained for the use of the investigational device and are familiar with the investigator 
responsibilities, etc.).  
Upon site initiation, a log shall be established identifying names, initials, signatures, 
functions , and designated authorities for the investigator and members of the 
investigation site team . In addition, a log for patient identification shall be issued.   
The findings of the study initiation visit shall be documented  
 
During the course of the investigation , the monitor shall conduct periodic monitoring 
visits, and where applicable discussions, to the investigational sites, according to 
predetermined schedu le or as required. During those visits, the study monitor shall 
audit the site and shall verify that:  
1. the facilities are still acceptable for the study;  
2. the study Protocol/ Investigational Plan , requirements of relevant 
International Standards, regulations and regulatory authorities ( e.g., FDA), 
any condition imposed by IRB, and the Investigator Agreement,  are being 
followed;  
3. any Protocol changes have been reported to the Spon sor and the IRB , and 
have been approved by the IRB , and, where applicable, other re gulatory 
authorities;  
4. accurate, complete and current records are maintained and are consistent 
with source documents ; 
5. special care should be taken to verify that the Informed Consent Forms are 
completed and signed accurately ( i.e., signed and dated informed consent 
forms have been obtained at the point of enrolment  or before any clinical -
investigation -related procedures were  undertaken ), and that adverse events 
are carefully monitored and reported;  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 110 of 117  
 
6. report s to the Sponsor and to the IRB  are accurate, complete and made in 
timely manner;  
7. appropriate corrections, additions or deletions are made to the CRFs, dated, 
explained if necessary , and initialed by the Investigator (or by his/her 
authorized designee ); the monitor shall not make  corrections, addition s or 
deletions to the CRFs ; 
8. the Investigator has not delegated activities to other staff which were not 
specified and authorized previously ; 
9. the investigational device is being used according to the protocol  and 
Instructions for Use and that, where  modific ations are required to the device  
or its method of use , these are reported to the S ponsor ; 
10. storage and investigational device accountability are correct and the 
traceability process is being  followed ;  
11. the investigator continues to have access to an adequate number of subjects 
and investigational devices ; 
12. the investigator and investigation site team are informed and knowledgeable 
of all relevant  document  updates concerning the clinical investigation ;  
13. any corrective and preventive actions , as needed, have been implemented and 
are effective.  
During the audit, study monitor may request study records, including source 
documents (individual subjects' records) for inspection and copying, and will compare 
them to the contents of reports  made to the Sponsor b y the Investigator to assure  
accuracy and completeness of the data. Any deficiencies noted will be corrected on 
site, if possible , according to correction instructions and adding the correct 
information. The correction shall be signed and dated by the Inve stigator. The finding 
of deficiencies may call for a review of a larger number of files or to rescheduling of 
the monitoring visits. Such decisions and the rationale for them will be recorded on 
the report made by the monitor to the Sponsor.  
In general, t he said comparison will ensure that:  
i. the information recorded in the Investigator’s report to the Sponsor is 
complete, accurate and legible;  
ii. there are no omission of data elements in the reports ; 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 111 of 117  
 
iii. missing visits and data elements are noted as such in the re ports ; 
iv. subjects failing to complete the study and the reason for that are documented 
in the reports ; 
v. informed consent is documented in accordance with the relevant regulations . 
 
The Investigator guarantees direct access to the study files, patient CRFs, an d patient 
medical records, to staff of the Sponsor/monitor.  
 
The last monitoring visit to the site shall be the Site Closure/Study Termination Visit , 
during which the monitor shall verify, in addition to all the above, that the 
Investigator records are complete, all documents needed for the Sponsor's files are 
retrieved, and previously identified issues have been resolved. In addition, the monitor 
shall verify that the Investigator returned all the devices to the Sponsor, according to 
the Sponsor instructions, unless this action would jeopardize the rights, safety or 
welfare of the subjects.  
 
The findings of the study periodic  and last monitoring visits shall be documented . 
All monitoring activities shall be forward in a writ ten report to the Sponsor. A copy of 
the monitoring report or a summary of key findings shall be shared with the 
Investigator in writing. The records will include, at a minimum, the following 
information:  
1. date of the visit;  
2. name of the monitor;  
3. Investigato r and site visited details, and of any other staff members present at 
the visit;  
4. a summary of the findings, conclusions, and any actions taken to correct any 
deficiencies noted during the visit.  
 
The monitor shall document  and maintain  a copy of all the re cords and reports of 
each visit/audit or other contact/communication with the site and Sponsor  during the 
investigation and for a period of 2 years after the latter of the following: (i) the date 
on which  the investigation is terminated or completed; or (i i) the date that the records 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 112 of 117  
 
are no longer required to support a regulatory notification to the authorities for the 
purpose of receiving a marketing clearance for the system in question.  
 
Adverse events  resulting from malfunction of the Investigational Dev ice, or any other 
clinical complications, should be reported to the Sponsor/ study monitor as described 
above (see Section 5.14.4.2 ). 
In case of any unanticipated adverse device effect, the Sponsor shall immediately 
conduct an evaluation.   
If suspicion of an unacceptable risk to subjects arises during the clinical investigation, 
or when so instructed by the IRB  or regulatory authorities, the Sponsor shall suspend  
the clinical investigation while the risk is assessed.  
The Sponsor shall terminate the clinica l investigation if an unacceptable risk is 
confirmed ( e.g., in case the sponsor determines that an unanticipated adverse device 
effect presents an unreasonable risk to subjects). The termination will occur within 5 
working days after the decision to termin ate the study is taken and no later than 15 
working days after first becoming aware of the adverse event. If the suspension or 
premature termination was in the interest of safety, the Sponsor shall inform all other 
investigators.  
If resumption of the suspended study is desired – the Sponsor shall noti fy the 
investigator and the IRB  (and if relevant – the regulatory authority) and provides them 
with t he rational and supporting data. Study resumption shall be only following a 
written  approval of the IRB . In the USA, resumption of terminated study is subjected 
to the regulation of CFR 21 part 812.46(c).    
 
The monitor shall immediately (and no later than 5 days following the discovery of 
such an occurrence) notify the Sponsor of any conditions of non -compl iance  with the  
signed Agreement, Protocol, Investigational Plan, conditions of IRB , FDA and/or 
other regulatory authorit y approval  and/or regulations . In case compliance cannot be 
secured, the Sponsor will discontinue shipments of the device to the non -complying 
investigator and terminate its participation in the investigation. The Sponsor shall also 
require such an Investigator to return the device s, unless this action would jeopardize 
the rights, safety, o r welfare of a subject.  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 113 of 117  
 
5.19 OPERATIONAL ISSUES  
5.19.1  TRAINING  
Investigators should be fully experienced with the use of pedicle screw systems and 
interbody fusion devices, and the required specialized spinal surgery techniques.  
Training of the investigating team re garding the investigational device and the study 
Protocol will be provided by the Sponsor personnel or its authorized representative(s) 
prior to commencing any study -related procedure.  
In particular, training of the Investigator will include a lecture and  demonstration 
(possibly electronically), as well as simulation of the use of the system in sawbones , 
according to the Training Protocol ( Attachment D ). Training, and Investigator 
competency with the device and compliance with training, will be documented.   
 
5.19.2  SUPPLY AND STORAGE (ACCOUNTABILITY ) 
The Sponsor will supply the CarboClear System (implants and surgical instruments), 
for the performance of the procedures within the scope of this study, for as long as the 
study is carried.  
The CarboClear  System  shall be used only in the clinical investigation and according 
to this Protocol.  
The Sponsor shall keep records to document the physical location of all 
investigational devices to the investigation sites until return or disposal.  
All investigational devi ces received and used by the Investigator will be inventoried 
and accounted for throughout the study. The devices will be stored in a secure area 
with restricted access, separate from other medical devices. When instructed by the 
Sponsor, the Investigator will return any remaining devices to the Sponsor. The 
Investigator will not supply the investigational device to any person except those 
designated by him/her as co-investigator(s). If a device is explanted from a patient for 
any reason, it should be retur ned to the Sponsor following instructions provided by 
the Sponsor and/or the study monitor.  
The Investigator shall keep records documenting the receipt, use, return and disposal 
of the investigational devices, which shall include the following details:  
1. Date of receipt;  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 114 of 117  
 
2. Identification of each investigational device ( e.g., lot number);  
3. Date of use;  
4. Subject identification;  
5. Date of return of unused, expired or malfunctioning investigational devices, 
if applicable.  
6. Date of investigational device disposal, if applicable.  
 
5.19.3  TRACEABILITY OF DEVICES AND DOCUMENTS  
Complete traceability of all devices will be maintained during the study. Records will 
include raw materials, manufacturing and inspection data, as well as implantation 
data.  
All documents and data shall be produced and maintained in a way that assures 
control and traceability. All documents, and subsequent versions, related to the 
clinical investigation shall be identifiable, traceable and appropriately stored to 
provide a complete history of the clinical  investigation.  
Each device shall be assigned with a lot number. The Sponsor will be responsible for 
product delivery, monitoring (CRF, etc.) and traceability records.  
The investigational site shall maintain a log of all the subjects enrolled in the clini cal 
investigation, assigning an identification code linked to their name. The Investigator 
will also maintain product inventory with traceability records and subject records.  
 
5.19.4  RECORD RETENTION  
Records related to the clinical study are subject to inspectio n by regulatory authorities 
and must be retained by the Sponsor and Investigator for a period as per regulations.  The 
files may be discarded only upon notification from Sponsor.  
 
The Investigator is responsible for retention (and where applicable, for the  
preparation, review and/or signing) of the following records:  
 All correspondence, which pertain to the investigation;  
 Device use/disposition and accountability records (as detailed above);  
 Subject's case history records, including:  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 115 of 117  
 
a. Signed Informed Consent  Form;  
b. All Protocol required evidences/observations;  
c. Observations of adverse events;  
d. Medical history;  
e. Documentation of the dates and reasons for any deviation from Protocol;  
f. Case Report Forms (CRFs):  
g. Patient Questionnaires.  
 
5.19.5  AMENDMENTS  
The Protocol, CRFs,  Informed Consent Form and other subject information, or other 
clinical investigation documents, may be amended as needed throughout the clinical 
investigation, and a justification statement shall be included with each amended 
section of a document. The ve rsion number and date of amendments shall be 
documented.  
 
Proposed amendments to the Protocol shall be agreed upon between the Sponsor and 
Principle Investigator, and the Sponsor shall incorporate the amendment into the 
document. The amendments to the Pro tocol and the subject’s Informed Consent Form 
shall be notified to the IRB by the Sponsor, or approved by the IRB (and regulatory 
authorities, if required).  
Non-substantial changes that do not affect the rights, safety and well -being of human 
subjects, or  that are not related to the clinical investigation objectives or endpoints, 
should be simply notified to the IRB.  
 
5.19.6  DEVIATIONS FROM PROTOCOL  
The Investigator is not allowed to deviate from the Protocol, except as specified 
below.  
Request for deviation from Protocol shall be agreed between the Sponsor and 
Investigator and communicate to the IRB by the Sponsor.  
Under emergency circumstances, deviations from the Protocol to protect the rights, 
safety and well -being of human subjects may proceed without prior approval of the 
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 116 of 117  
 
Sponsor and the IRB. Such deviations shall be documented by the Investigator and 
reported to the Sponsor as soon as possible and to the IRB.  
 
5.19.7  PUBLICATION  
The results of this study may be submitted for publication. In case the study results 
are published, the participating subjects ' identity will not be disclosed.  
The ownership of the data shall, at all times, be held by the Sponsor.  
The Sponsor reserves the right to include the report of this clinical investigation in 
any regulatory documentation or submission or in any informational materials 
prepared for the medical profession.  
Upon approval by the Sponsor, Investigators are permit ted to present the data at 
symposia, professional meetings, and to publish in journals, theses or dissertations 
methods and results of the study. Investigators agree to delay presentation or 
publication of study results until agreed to by all contributing centers, and by the 
Sponsor.  
 
 
 
  
                                                                                                                         
 
 
                                                                                                                            CARBO CLEAR PEDICLE SCREW SYSTEM   
CARBOCLEAR P_ CLD 2492_US _IRBs_ 003_0 5/2017               CONFIDENTIAL          Page 117 of 117  
 
 
APPENDICES  
Appendix A  – Surgical Technique  
Appendix B  – Control Table  
Appendix C  – Training Protocol  
Appendix D  – Radiographic Protocol  
Appendix E  – Patient Informed Consent  
Appendix F  – CRFs and Patients Questionnaires  
 